FOAs & Notices

Advancing Genomic Medicine Research (R01 Clinical Trial Optional), RFA-HG-23-032, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI)

Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed), RFA-HG-23-048, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)

Advancing Genomic Medicine Research (R21 Clinical Trial Optional), RFA-HG-23-033, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI)

Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional), PAR-23-293, National Institutes of Health (NIH), Fogarty International Center (FIC), National Human Genome Research Institute (NHGRI), National Eye Institute (NEI), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI), National Institute on Minority Health and Health Disparities (NIMHD), Office of Research on Women's Health (ORWH)

Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional), PAR-23-295, National Institutes of Health (NIH), Fogarty International Center (FIC), National Human Genome Research Institute (NHGRI), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Cancer Institute (NCI), Office of Data Science Strategy (ODSS), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women's Health (ORWH)

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional), PAR-23-294, National Institutes of Health (NIH), Fogarty International Center (FIC), National Human Genome Research Institute (NHGRI), National Eye Institute (NEI), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women's Health (ORWH)

Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional), PAR-24-059, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), Office of Disease Prevention (ODP), Office of Research on Women's Health (ORWH)

Comprehensive Alcohol-HIV/AIDS Research Center (P60 Clinical Trial Optional), RFA-AA-23-004, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required), RFA-MD-24-003, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), Sexual and Gender Minority Research Office (SGMRO), Office of Research on Women's Health (ORWH)

HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R01 Clinical Trial Optional), RFA-AA-23-005, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R34 Clinical Trial Optional), RFA-AA-23-006, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional), RFA-MD-24-001, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional), RFA-NS-24-021, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Career Enhancement Award to Advance the Study of Intimate Partner Violence (IPV) in the Context of Maternal Morbidity and Mortality Research (K18 Clinical Trial Not Allowed), RFA-OD-24-001, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Nursing Research (NINR), Sexual and Gender Minority Research Office (SGMRO), Office of Disease Prevention (ODP), Office of Research on Women's Health (ORWH)

Community-Engaged Health Equity Research in Neuroscience Initiative (R34 CT Not Allowed), RFA-NS-24-007, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

Community-Engaged Health Equity Research in Neuroscience Initiative (R01 CT Not Allowed), RFA-NS-24-006, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

Public Health Communication Messaging about the Continuum of Risk for Tobacco Products (U01 Clinical Trial Required), RFA-OD-23-021, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Office of Disease Prevention (ODP), National Cancer Institute (NCI)

Network of Genomics-Enabled Learning Health Systems (gLHS) - Coordinating Center (U01 Clinical Trials Required), RFA-HG-23-042, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)

Network of Genomics-Enabled Learning Health Systems (gLHS) - Clinical Sites (U01 Clinical Trial Required), RFA-HG-23-041, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)

HEAL Initiative: Toward Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required), RFA-AT-24-003, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)

Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional), RFA-HG-23-017, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Cancer Institute (NCI)

Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional), RFA-HG-23-018, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA)

Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional), RFA-MH-24-120, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors – Clinical Centers (U01 Clinical Trial Not Allowed), RFA-DK-23-010, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-23-017, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Cancer Institute (NCI)

Emergency Award: RADx-®UP Dissemination and Implementation (D&I) Research on COVID-19 Testing Interventions among Underserved and Vulnerable Populations (R01 Clinical Trial Optional), RFA-OD-23-051, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional), RFA-NS-23-028, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed), RFA-TR-23-011, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Advancing Integrated Models (AIM) of Care to Improve Pregnancy Outcomes among Women Who Experience Persistent Disparities (R01 Clinical Trial Optional), RFA-NR-23-002, National Institutes of Health (NIH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 - Clinical Trial Optional), RFA-MD-23-004, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)

Pilot Interventions to Integrate Social Care and Medical Care to Improve Health Equity (R01 Clinical Trial Required), RFA-DK-22-038, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required), PAR-23-090, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional), RFA-DA-24-037, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Career Enhancement Award to Advance Research on Firearm Injury and Mortality Prevention (K18 Independent Clinical Trial Not Allowed), PAR-23-108, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)

Career Enhancement Award to Advance Research on Firearm Injury and Mortality Prevention (K18 Independent Clinical Trial Required), PAR-23-107, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)

Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 – Clinical Trial Optional), PAR-23-112, National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Minority Health and Health Disparities (NIMHD), National Eye Institute (NEI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH)

Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required), RFA-MH-23-170, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

NIDA Program Project Grant Applications (P01 Clinical Trial Optional), PAR-23-064, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required), RFA-NS-23-012, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), Office of The Director, National Institutes of Health (OD)

Research Centers in Minority Institutions (RCMI) (U54 Clinical Trial Optional), RFA-MD-23-001, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)

Research on Community Level Interventions for Firearm and Related Violence, Injury and Mortality Prevention (CLIF-VP) (UG3/UH3 Clinical Trial Required), PAR-23-066, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), Sexual and Gender Minority Research Office (SGMRO)

Interventions that Address Structural Racism to Reduce Kidney Health Disparities - Research Coordinating Center (U24 - Clinical Trial Not Allowed), RFA-DK-23-003, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional), RFA-DA-23-059, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI)

HEAL Initiative - Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program: Leadership and Data Co-ordinating Center (U01 Clinical Trial Optional), RFA-DA-23-060, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI)

Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed), RFA-DA-24-002, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required), RFA-OD-22-026, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed), RFA-OD-22-025, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required), RFA-OD-22-024, , National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed), RFA-OD-22-023, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain (RM1 Clinical Trial Optional), RFA-NS-22-069, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Community Partnerships to Advance Science for Society (ComPASS): Coordination Center (U24 Clinical Trial Optional), RFA-RM-23-001, National Institutes of Health (NIH), Office of Strategic Coordination (Common Fund)

Advancing Adolescent Tobacco Cessation Intervention Research (R34 Clinical Trial Optional), RFA-CA-22-042, National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA)

Advancing Adolescent Tobacco Cessation Intervention Research (R01 Clinical Trial Required), RFA-CA-22-043, National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional), RFA-DA-23-061, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional), RFA-DA-23-062, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: HEAL Data2Action – Acceleration Projects (R33 Clinical Trial Not Allowed), RFA-DA-23-058, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards (R61/R33, Clinical Trial Optional), RFA-DA-23-057, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Prevention and Management of Chronic Pain in Rural Populations (UG3/UH3, Clinical Trials Required), RFA-NR-23-001, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health Sciences (NIEHS), National Cancer Institute (NCI), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI)

Limited Competition: The NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL) (U24 Clinical Trial Not Allowed), RFA-HG-22-020, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional), PAR-22-202, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)National Institute on Drug Abuse (NIDA)

Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional), PAR-22-200, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Environmental influences on Child Health Outcomes (ECHO) Data Analysis Center (U24 Clinical Trial Not Allowed), RFA-OD-22-022, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS)

Environmental influences on Child Health Outcomes (ECHO) Measurement Core (U24 Clinical Trial Not Allowed), RFA-OD-22-020, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS)

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R21 Basic Experimental Studies with Humans Required), RFA-HD-23-033, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R21 Clinical Trial Not Allowed), RFA-HD-23-031, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Clinical Trial Not Allowed), RFA-HD-23-030, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Basic Experimental Studies with Humans Required), RFA-HD-23-032, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed), RFA-EB-22-002, National Institutes of Health (NIH), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Development and validation of virtual assessments to study children and caregivers in their natural environment (R01- Clinical Trial Not Allowed), RFA-DA-23-050, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Development and validation of virtual assessments to study children and caregivers in their natural environment (R01- Basic Experimental Studies with Humans Required), RFA-DA-23-055, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)

Maternal Health Research Centers of Excellence Data Innovation and Coordinating Hub/Resource Center (U24 Clinical Trial Not Allowed), RFA-HD-23-036, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Office of AIDS Research (OAR), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), Sexual and Gender Minority Research Office (SGMRO)

AD/ADRD, Adverse Childhood Experiences, and Social Determinants of Health Ancillary Studies of Existing Longitudinal Cohorts (R01 - Clinical Trial Not Allowed), PAR-22-221, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA)

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional), RFA-DA-23-032, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional), RFA-DA-23-031, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional), RFA-DA-23-029, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional), RFA-DA-23-028, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional), RFA-DA-23-026, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Coordination Center to Support Racial Equity and Substance Use Disparities Research (U24 Clinical Trial Not Allowed), RFA-DA-23-025, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional), RFA-DA-23-024, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional), RFA-DA-23-023, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional), RFA-DA-23-013, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain (R01 Clinical Trial Not Allowed), RFA-NS-22-070, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Oral Complications Arising from Pharmacotherapies to Treat Opioid Use Disorders (R21 Clinical Trial Not Allowed), RFA-DE-23-016, National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Oral Complications Arising from Pharmacotherapies to Treat Opioid Use Disorders (R01 Clinical Trial Not Allowed), RFA-DE-23-015, National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional), RFA-DA-23-054, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional), RFA-DA-23-053, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional), RFA-NS-23-003, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Interventions that Address Structural Racism to Reduce Kidney Health Disparities - (U01 - Clinical Trial Required), RFA-DK-22-014, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

Interventions that Address Structural Racism to Reduce Kidney Health Disparities - Research Coordinating Center (U24 - Clinical Trial Not Allowed), RFA-DK-22-015, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Research Studies to Develop and Implement Interventions to Prevent Opioid Misuse in Community Health Centers (R61/R33 Clinical Trial Required), RFA-DA-23-048, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

NIH HEAL Initiative: Coordinated Approaches to Pain Care in Health Care Systems (UG3/UH3 - Clinical Trial Optional), RFA-NS-22-053, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Coordinated Pain Care in Health Care Systems Research Program - Coordinating Center (U24 Clinical Trial Not Allowed), RFA-NS-22-065, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH)

Expanding Collaborative Implementation Science to Address Social and Structural Determinants of Health and Improve HIV Outcomes (R01 Clinical Trial Required), RFA-MH-22-190, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA)

Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional), PAR-22-210, National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required), PAS-22-206, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required), PAS-22-207, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required), RFA-AT-23-002, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Advancing Translational Sciences (NCATS)

HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional), RFA-AT-23-001, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 - Clinical Trials Optional), RFA-DA-23-051, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Understanding the Pathophysiology and Clinical Course of New-Onset Diabetes Following COVID-19 (U01 Clinical Trial Not Allowed), RFA-DK-22-016, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL) (R01 Clinical Trial Required), RFA-DA-23-041, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL): Resource Center (U24- Clinical Trial Optional), RFA-DA-23-042, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH)

New Epidemiological Cohort Study among Asian Americans, Native Hawaiians, and Pacific Islanders (AsA-NHPI): Clinical/Community Field Centers (UG3/UH3 - Clinical Trial Not Allowed), RFA-HL-23-015, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH)

HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed), RFA-DA-23-045, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On (RM1 - Clinical Trial Optional), RFA-DA-23-046, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)

Enabling SUD Digital Therapeutics Research to Improve Payor Adoption (R44- Clinical Trial Only), RFA-DA-23-018, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA Program Project Grant Applications (P01 Clinical Trial Optional), PAR-22-201, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed), RFA-DA-23-017, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed), RFA-DA-23-052, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional), RFA-DA-23-020, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional), RFA-DA-23-019, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Stakeholder Engagement Innovation Center for Advancing Health Equity in Type 2 Diabetes Research (U2C - Clinical Trial Not Allowed), RFA-DK-22-001, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data Management Coordinating Center for Diagnostic Centers of Excellence (U2C Clinical Trial Not Allowed), RFA-NS-22-051, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Human Genome Research Institute (NHGRI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Research Coordinating Center to Support Climate Change and Health Community of Practice (U24 - Clinical Trial Not Allowed), RFA-ES-22-003, National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), Fogarty International Center (FIC), National Cancer Institute (NCI)

NINDS Interdisciplinary Team Science Grant (RM1 Clinical Trial Optional), RFA-NS-22-036, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required), RFA-NS-22-071, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), Office of The Director, National Institutes of Health (OD)

Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional), PAR-22-182, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional), PAR-22-183, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional), PAR-22-167, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of General Medical Sciences (NIGMS), National Institute on Minority Health and Health Disparities (NIMHD)

Emergency Awards: HEAL Initiative: Coordinating Center for National Pain Scientists Career Development (R24 Clinical Trial Not Allowed), RFA-NS-22-060, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH)

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed), RFA-DA-23-040, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed), RFA-NS-22-052, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Small Research Grants for Analysis, Curation, and/or Sharing of Down syndrome-related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed), RFA-OD-22-008, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)

Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required), RFA-DA-23-002, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trial Required), RFA-OD-22-010, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)

Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed), RFA-OD-22-009, National Institutes of Health (NIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)

INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed), RFA-OD-22-007, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)

Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional), PAR-22-145, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Mental Health (NIMH), National Library of Medicine (NLM)

Implementation Research to Reduce Noncommunicable Disease (NCD) Burden in Low- and Middle-Income Countries (LMICs) and Tribal Nations During Critical Life Stages and Key Transition Periods (R01 Clinical Trial Optional), PAR-22-132, National Institutes of Health (NIH), Fogarty International Center (FIC), National Eye Institute (NEI), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI)

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional), RFA-DA-23-021, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional), RFA-MD-22-008, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI)

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed), PAR-22-138, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD)

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed), PAR-22-137, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD)

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional), PAR-22-133, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R21 - Clinical Trial Not Allowed), RFA-DA-23-009, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R34 - Clinical Trial Optional), RFA-DA-23-010, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Addressing Mental Health Disparities Research Gaps: Aggregating and Mining Existing Data Sets for Secondary Analyses (R01 Clinical Trial Not Allowed), RFA-MH-22-200, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54 Clinical Trial Optional), RFA-OD-22-004, National Institutes of Health (NIH), , U.S. Food and Drug Administration (FDA), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS)

Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54 Clinical Trial Not Allowed), RFA-OD-22-003, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA)

Research on Community Level Interventions for Firearm and Related Violence, Injury and Mortality Prevention (CLIF-VP) (UG3/UH3 Clinical Trial Optional), PAR-22-115, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)

Coordinating Center to Support Research on Community Level Interventions for Firearm and Related Violence, Injury and Mortality Prevention (CLIF-VP) (U24 Clinical Trial Not Allowed), PAR-22-120, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)

Limited Competition for the Continuation of the Data Coordinating Center for the Diabetic Foot Consortium (U24 Clinical Trial Optional), RFA-DK-21-505, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R01 Clinical Trial Required), RFA-DA-23-006, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R34 Clinical Trial Required), RFA-DA-23-007, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Emergency Awards: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trial Optional), RFA-OD-22-005, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

Emergency Award: RADx-UP Community-Engaged Research on Rapid SARS-CoV-2 Testing among Underserved and Vulnerable Populations (U01 Clinical Trial Optional), RFA-OD-22-006, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 Clinical Trial Optional), RFA-DA-23-003, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional), RFA-NS-22-050, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes & Cells (U19 Clinical Trial Not Allowed), RFA-NS-22-018, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Human Pain-associated Genes & Cells Data Coordination and Integration Center (U24 Clinical Trial Not Allowed), RFA-NS-22-021, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Required), PAR-22-112, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Optional), PAR-22-113, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Advancing Integrated Models (AIM) of Care to Improve Maternal Health Outcomes among Women Who Experience Persistent Disparities (R01 Clinical Trial Required), RFA-NR-22-002, National Institutes of Health (NIH), National Institute of Nursing Research (NINR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed), RFA-DE-22-011, National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

Emergency Award HEAL Initiative: Optimizing Existing Evidence-Based Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional), RFA-MH-22-175, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

Emergency Award HEAL Initiative: Developing and Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional), RFA-MH-22-176, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed), RFA-TR-22-013, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required), RFA-NS-22-037, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 Clinical Trial Optional), RFA-MD-22-007, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH)

Emergency Awards: HEAL Initiative-Limited Competition: HEAL Initiative Resource Centers for the Pain Management Effectiveness Research Network (ERN) (U24 Clinical Trial Not Allowed), RFA-TR-22-012, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH), National Center for Advancing Translational Sciences (NCATS), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional), RFA-DA-22-038, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional), RFA-DA-22-037, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: National K12 Clinical Pain Career Development Program (K12 Clinical Trial Not Allowed), RFA-NS-22-045, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Coordinating Center for National Pain Scientists Career Development (R24 Clinical Trial Not Allowed), RFA-NS-22-046, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Restoring Joint Health and Function to Reduce Pain Consortium (RE-JOIN) (UC2 Clinical Trial Not Allowed), RFA-AR-22-009, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed), RFA-NS-22-034, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

HEAL Initiative: HEAL Data2Action Modeling and Economic Resource Center (U24 Clinical Trial Optional), RFA-DA-049, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: HEAL Data2Action Research Adoption Support Center (U2C Clinical Trial Optional), RFA-DA-22-050, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional), RFA-DA-22-051, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Pilot & Feasibility Trials to Improve Prevention and Treatment Service Delivery for Polysubstance Use (R34 Clinical Trial Optional), RFA-DA-22-048, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional), RFA-DA-22-047, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional), RFA-DA-22-046, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Research Networks for the Study of Recovery Support Services for Persons Treated with Medications for Opioid Use Disorder (R24 Clinical Trial Optional), RFA-DA-22-043, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders: Coordination Center (R24 Clinical Trial Optional), RFA-DA-22-042, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

HEAL Initiative: Planning Grants for Efficacy or Effectiveness Trials of Recovery Support Services for Individuals Treated with Medications for Opioid Use Disorder (R34 Clinical Trial Optional), RFA-DA-22-034, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21- Clinical Trial Not Allowed), RFA-DA-22-045, National Institutes of Health, National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed), RFA-DA-22-044, National Institutes of Health, National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH)

Center for Rapid Surveillance of Tobacco (CRST) to Assess Changes in Use Behaviors, Product Marketing, and the Marketplace (U01 Clinical Trial Not Allowed), RFA-OD-22-002, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), National Cancer Institute (NCI)

Risk and Protective Factors of Family Health and Family Level Interventions (R01 - Clinical Trial Optional), PAR-21-358, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Nursing Research (NINR), National Cancer Institute (NCI)

Research Centers in Minority Institutions (RCMI) (U54 Clinical Trials Optional), RFA-MD-22-002, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)

NIH HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 Clinical Trials Optional), RFA-DA-22-036, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Mental Health (NIMH)

Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities (R01 Clinical Trial Optional), PAR-22-064, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Deafness and Other Communication Disorders (NIDCD)

Understanding Place-Based Health Inequalities in Mid-Life (R01 Clinical Trial Not Allowed), RFA-AG-23-004, National Institutes of Health (NIH)

HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required), RFA-AT-22-003, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS)

Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required), RFA-MH-22-150, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Home and Community-Based Physical Activity Interventions to Improve the Health of Wheelchair Users (R01 Clinical Trial Required), RFA-HD-22-017, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required), RFA-AT-22-005, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Advancing Translational Sciences (NCATS)

HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional), RFA-AT-22-004, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

Clinical Research Education and Career Development (CRECD) Program (R25-Independent Clinical Trial Not Allowed), PAR-21-347, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Nursing Research (NINR)

NIH Health Care Systems Research Collaboratory - Pragmatic and Implementation Trials of Embedded Interventions (UG3/UH3, Clinical Trials Optional), RFA-AT-22-001, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required), RFA-NS-22-002, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional), RFA-ES-21-007, National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS)

Pediatric Obesity Discovery Science Research to Improve Understanding of Risk and Causal Mechanisms for Obesity in Early Life (R01 Clinical Trial Optional), RFA-DK-21-025, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

HEAL initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression Without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development) (UG3/UH3 Clinical Trials Not Allowed), RFA-HL-22-013, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA)

Investigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Exploratory/Developmental Research Grant Award (R21 Clinical Trial Not Allowed), RFA-OD-21-007, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP), National Cancer Institute (NCI)

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional), PAS-21-270, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immunogenicity in Severe Hemophilia A: Hemophilia A Analytical Cohort Research Program (UG3/UH3 Clinical Trial Not Allowed), RFA-HL-22-004, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

High Priority HIV and Substance Use Research (R01 Clinical Trial Optional), RFA-DA-22-040, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R01 - Clinical Trial Optional), RFA-DA-22-028, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R21 - Clinical Trial Optional), RFA-DA-22-039, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional), PAR-22-027, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional), RFA-NS-22-016, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS)

Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional), RFA-DA-22-022, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional), PAR-21-303, National Institutes of Health (NIH)

Imaging - Science Track Award for Research Transition (I/START) (R03- Basic Experimental Studies with Humans Required), PAR-21-309, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Imaging - Science Track Award for Research Transition (I/START) (R03- Clinical Trial Optional), PAR-21-310, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Advancing Validated Drug Targets for Substance Use Disorders (R41/R42 - Clinical Trial Not Allowed), RFA-DA-22-018, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed), RFA-DA-22-033, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional), RFA-DA-23-001, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed), RFA-DA-22-032, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed), RFA-DA-22-031, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

Exploratory Studies to Investigate the Mechanisms of Interrelationship between Sleep and Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans Required), RFA-DA-22-029, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional), PAR-21-275, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Cancer Institute (NCI)

Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R34 Clinical Trial Required), RFA-MH-21-241, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R01 Clinical Trial Required), RFA-MH-21-240, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Elucidating the Effects of ART on Neuronal Function in the Context of SUD and HIV (R01 - Clinical Trials Not Allowed), RFA-DA-22-003, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Large Scale Mapping and/or Molecular Profiling of Ensembles and/or Cell-Types Mediating Opioid Action in the Rodent Brain (R01 - Clinical Trial Not Allowed), RFA-DA-22-011, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Organoid Modeling of Neural Stimulants and HIV Comorbidity of Human Brain (R01- Clinical Trial Optional), RFA-DA-22-009, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional), RFA-DA-22-017, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA Animal Genomics Program (U01 - Clinical Trial Not Allowed), PAR-21-244, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Exploratory Studies to Investigate the Mechanisms of Interrelationship Between Sleep and Substance Use Disorders (R61/R33 Clinical Trials Not Allowed), RFA-DA-22-016, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Assessing the Effects of Cannabinoids on HIV-Associated Persistent Inflammation (R01 Clinical Trial Optional), RFA-DA-22-012, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Basic Experimental Studies with Humans Required), RFA-DA-22-030, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Basic Experimental Studies with Humans Required), RFA-DA-22-024, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 Clinical Trial Not Allowed), RFA-DA-22-007, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mechanistic studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Clinical Trial Not Allowed), RFA-DA-22-005, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required), PAR-21-237, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional), PA-21-180, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required), PA-21-205, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional), RFA-DA-22-001, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required), RFA-MH-21-230, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

NIMHD Multiple Chronic Disease Disparities Research Coordinating Center (RCC) (U24 Clinical Trial Not Allowed), RFA-MD-21-008, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)

Centers for Multiple Chronic Diseases Associated with Health Disparities: Prevention, Treatment, and Management (P50 Clinical Trial Required), RFA-MD-21-007, National Institute on Minority Health and Health Disparities (NIMHD)

Emergency Award: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional), RFA-OD-21-009, National Institutes of Health (NIH)

Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations - RADx-UP Phase II (U01 Clinical Trial Optional), RFA-OD-21-008, National Institutes of Health (NIH)

Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed), RFA-DA-22-021, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R43/R44 - Clinical Trial Not Allowed), RFA-DA-22-019, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed), PAR-21-213, National Institutes of Health (NIH) National Institute on Aging (NIA), National Eye Institute (NEI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD)

Limited Competition Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed), RFA-DA-22-002, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional), PAR-21-208, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional), PAR-21-183, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional), RFA-MD-21-004, National Institutes of Health (NIH)

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required), PAR-21-132, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-21-002, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA)

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed), RFA-AA-21-003, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed), RFA-AA-21-002, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism. (NIAAA)

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed), RFA-AA-21-004, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed), RFA-DA-22-004, National Institutes of Health, National Institute on Drug Abuse (NIDA)

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed), PAR-21-062, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required), RFA-DA-21-030, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Mental Health; National Center for Complement

HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Coordination and Dissemination Center (R24 Clinical Trial Optional), RFA-DA-21-029, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Mental Health; National Center for Complement

HEAL Initiative: HEALthy Brain and Child Development Study (Collaborative U01- Clinical Trial Not Allowed), RFA-DA-21-020, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; National Institute of Child Health and Human Development; National Institute

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed), PAR-21-062, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases

Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional), PAS-21-031, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases

Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed), RFA-HG-22-010, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)

Multi-Omics for Health and Disease - 'Omics Production Centers (U01 Clinical Trial Not Allowed), RFA-HG-22-009, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)

Multi-Omics for Health and Disease - Disease Study Sites (U01 Clinical Trial Optional), RFA-HG-22-008, National Institutes of Health (NIH), National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional), PAR-21-092, National Institutes of Health; National Institute on Drug Abuse

Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with, RFA-OD-20-023, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases;

Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional), RFA-OD-20-022, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Aging; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Diso

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed), RFA-OD-20-021, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Nat

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed), RFA-OD-20-020, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Nat

Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed), RFA-OD-20-019, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of

Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed), RFA-OD-20-018, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; National Institute on Aging; National Institute of Dental and Craniofacial Research;

Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed), RFA-OD-20-017, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculosk

Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional), RFA-OD-20-016, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Disea

Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed), RFA-OD-20-015, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Drug Abuse; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Library of Medicine; This

Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed), RFA-OD-20-014, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Nationa

Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional), PAR-20-286, National Institutes of Health; National Institute of Mental Health

Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional), PAR-20-279, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

NIDA Core Center of Excellence Grant Program (P30 Clinical Trial Optional), PAR-20-267, National Institutes of Health; National Institute on Drug Abuse

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional), PAR-20-249, National Institutes of Health; National Institute on Drug Abuse

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional), PAR-20-237, National Institutes of Health; National Institute on Minority Health and Health Disparities; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health

Improving Smoking Cessation Interventions among People Living with HIV (R21 Clinical Trial Optional), RFA-CA-20-036, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse

Improving Smoking Cessation Interventions among People Living with HIV (R01 Clinical Trial Optional), RFA-CA-20-035, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse; National Institute on Minority Health and Health Disparities

Advancing Genomic Medicine Research (Clinical Trial Optional) (R21), RFA-HG-20-037, National Institutes of Health; National Human Genome Research Institute

Advancing Genomic Medicine Research (Clinical Trial Optional) (R01), RFA-HG-20-036, National Institutes of Health; National Human Genome Research Institute

Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional), RFA-OD-20-013, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Minority Health and Health Disparities; National Institute on Aging; National Eye Institute; National Heart, Lung, and Blood Institute; National Hu

NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional), PAR-20-221, National Institutes of Health; National Institute on Drug Abuse

Post-Acute Interventions for the Treatment of Anorexia Nervosa (R34 Clinical Trial Required), RFA-MH-20-500, National Institutes of Health; National Institute of Mental Health

NIDA Small Research Grant Program (R03 Clinical Trial Required), PA-20-146, National Institutes of Health; National Institute on Drug Abuse

Implementing the HIV Service Cascade for Justice-Involved Populations (U01 Clinical Trial Required), RFA-DA-20-028, National Institutes of Health; National Institute on Drug Abuse

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required), RFA-OD-20-011, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; U.S. Food and Drug Administration, Center for Tobacco Products

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required), RFA-OD-20-010, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed), RFA-OD-20-009, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed), RFA-OD-20-008, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional), PAR-20-092, National Institutes of Health; National Institute on Drug Abuse

Genomic Community Resources (U24 Clinical Trial Not Allowed), PAR-20-100, National Institutes of Health; National Human Genome Research Institute; National Cancer Institute

Safety and Feasibility Trials for Rapid-Acting Interventions for Severe Suicide Risk (R01 Clinical Trial Required), RFA-MH-20-345, National Institutes of Health; National Institute of Mental Health

Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R01 Clinical Trial Optional), RFA-MH-20-505, National Institutes of Health; National Institute of Mental Health

Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R34 Clinical Trial Required), RFA-MH-20-506, National Institutes of Health; National Institute of Mental Health

Enhancing Suicide Prevention in Emergency Care via Telehealth (R01 Clinical Trial Optional), RFA-MH-20-226, National Institutes of Health; National Institute of Mental Health

Early Psychosis Intervention Network (EPINET): Practice-Based Research to Improve Treatment Outcomes (R01 Clinical Trial Optional), RFA-MH-20-205, National Institutes of Health; National Institute of Mental Health

Dysregulation and Proximal Risk for Suicide (R01 Clinical Trial Optional), RFA-MH-20-327, National Institutes of Health; National Institute of Mental Health

Dysregulation and Proximal Risk for Suicide (R21 Clinical Trial Optional), RFA-MH-20-326, National Institutes of Health; National Institute of Mental Health

Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (Collaborative U01 Clinical Trial Not Allowed), PAR-20-027, National Institutes of Health; National Institute of Mental Health

Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (U01 Clinical Trial Not Allowed), PAR-20-026, National Institutes of Health; National Institute of Mental Health

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-19-028, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Environment

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional), PAR-19-368, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute

The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required), RFA-DA-20-024, National Institutes of Health; National Institute on Drug Abuse

NIDA Program Project Grant Applications (P01 Clinical Trial Optional), PAR-19-345, National Institutes of Health; National Institute on Drug Abuse

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional), PAR-19-327, National Institutes of Health; National Institute on Drug Abuse

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01-Clinical Trial Optional), PAR-19-318, National Institutes of Health; National Institute on Drug Abuse

Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed), RFA-DA-20-023, National Institutes of Health; National Institute on Drug Abuse

Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional), PAR-19-310, National Institutes of Health; National Institute on Drug Abuse

PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional), RFA-DA-20-013, National Institutes of Health; National Institute on Drug Abuse

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional), PAR-19-259, National Institutes of Health; National Institute on Drug Abuse

Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed), RFA-HL-20-014, National Institutes of Health; National Heart, Lung, and Blood Institute; National Center for Advanced of Translational Sciences

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis, Informatics and Resource Center (U24 Clinical Trial Not Allowed), RFA-DA-20-003, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Linked Research Project Sites (Collaborative U01 Clinical Trial Not Allowed), RFA-DA-20-002, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Coordinating Center (U24 Clinical Trial Not Allowed), RFA-DA-20-004, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required), PAR-19-236, National Institutes of Health; National Institute of Mental Health

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required), PAR-19-235, National Institutes of Health; National Institute of Mental Health

Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional), PAR-19-212, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), PAR-19-213, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Centers of Excellence in Genomic Science (RM1 Clinical Trials Optional), PAR-19-204, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-19-019, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Refinement and Testing of Interventions to Sustain ADHD Treatment Effects Across Settings and Developmental Transitions (R34 Clinical Trial Required), RFA-MH-20-100, National Institutes of Health; National Institute of Mental Health

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed), PAR-19-162, National Institutes of Health; National Institute on Drug Abuse; National Institute on Minority Health and Health Disparities; National Institute of Mental Health; National Cancer Institute; National Center for Complementary and Integrative Health; Nation

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed), PAR-19-163, National Institutes of Health; National Institute on Drug Abuse; National Institute of Neurological Disorders and Stroke; National Institute on Minority Health and Health Disparities; National Institute of Mental Health; National Cancer Institute; Eunice

Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders (UG1 Clinical Trial Required), RFA-DA-19-018, National Institutes of Health; National Institute on Drug Abuse

HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) (UG3/UH3 Clinical Trial Required), RFA-DA-19-035, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute of Child Health and Huma

HEAL Initiative: Effectiveness Trials to Optimize, Implement, Scale, and Sustain the Collaborative Care Model for Individuals with Opioid Use Disorders and Mental Health Conditions (U01 Clinical Trial Required), RFA-MH-19-525, National Institutes of Health; National Institute of Mental Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Nursing Research; National Institute on Minority H

HEAL Initiative: Coordinating Center to Support NIDA Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) Initiative (U24 Clinical Trial Not Allowed), RFA-DA-19-034, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute of Child Health and Huma

HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Clinical Research Centers (UG1 Clinical Trial Optional), RFA-DA-19-025, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Coordination and Translation Center (U2C Clinical Trial Optional), RFA-DA-19-024, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Methodology and Advanced Analytics Resource Center (U2C Clinical Trial Not Allowed), RFA-DA-19-023, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed), PA-19-043, National Institutes of Health; National Human Genome Research Institute

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional), PAR-19-064, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

HEALing Communities Study: Developing and Testing an Integrated Approach to Address the Opioid Crisis (Data Coordinating Center) (UM1 - Clinical Trials Not Allowed), RFA-DA-19-017, National Institutes of Health; Substance Abuse and Mental Health Services Administration; National Institute on Drug Abuse

HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional), PAS-18-915, National Institutes of Health; National Institute on Drug Abuse

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional), PA-18-916, National Institutes of Health; National Institute on Drug Abuse

Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional), PAR-18-918, National Institutes of Health; National Institute on Drug Abuse

Responding to Opioid Use Disorders (OUD) in Tribal Communities in the Context of SAMHSA and CDC Funding (R61/R33 - Clinical Trials Optional), RFA-DA-19-013, National Institutes of Health; National Institute on Drug Abuse; Office of Behavioral and Social Sciences Research; Tribal Health Research Office

HEALing Communities Study: Developing and Testing an Integrated Approach to Address the Opioid Crisis (Research Sites) (UM1 - Clinical Trial Required), RFA-DA-19-016, National Institutes of Health; Substance Abuse and Mental Health Services Administration; National Institute on Drug Abuse

The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Optional), RFA-DA-19-008, National Institutes of Health; National Institute on Drug Abuse

Dysregulation and Proximal Risk for Suicide FOA (R01 Clinical Trial Optional), RFA-MH-19-211, National Institutes of Health; National Institute of Mental Health

Dysregulation and Proximal Risk for Suicide (R21 Clinical Trial Optional), RFA-MH-19-210, National Institutes of Health; National Institute of Mental Health

Improving Smoking Cessation Interventions among People Living with HIV (R21 Clinical Trial Optional), RFA-CA-18-028, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse

Improving Smoking Cessation Interventions among People Living with HIV (R01 Clinical Trial Optional), RFA-CA-18-027, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse; National Institute on Minority Health and Health Disparities

Early Psychosis Intervention Network (EPINET): Data Coordinating Center (U24 Clinical Trial Not Allowed), RFA-MH-19-151, National Institutes of Health; National Institute of Mental Health

Early Psychosis Intervention Network (EPINET): Practice-Based Research to Improve Treatment Outcomes (R01 Clinical Trial Optional), RFA-MH-19-150, National Institutes of Health; National Institute of Mental Health

Novel Approaches for Relating Genetic Variation to Function and Disease (R21 Clinical Trial Not Allowed), PA-18-867, National Institutes of Health; National Human Genome Research Institute

Novel Approaches for Relating Genetic Variation to Function and Disease (R01 Clinical Trial Not Allowed), PA-18-868, National Institutes of Health; National Human Genome Research Institute

Rare Genetic Syndromes as a Window into the Genetic Architecture of Mental Disorders (Collaborative U01 Clinical Trial Not Allowed), RFA-MH-19-201, National Institutes of Health; National Institute of Mental Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development

Rare Genetic Syndromes as a Window into the Genetic Architecture of Mental Disorders (U01 Clinical Trial Not Allowed), RFA-MH-19-200, National Institutes of Health; National Institute of Mental Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development

Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed), PAR-18-789, National Institutes of Health; National Institute on Drug Abuse

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed), RFA-OD-18-005, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; National Institute of Environmental Health Sciences

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required), RFA-OD-18-006, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required), RFA-OD-18-008, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed), RFA-OD-18-007, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; National Institute of Environmental Health Sciences

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 - Clinical Trial Optional), PA-18-780, National Institutes of Health; National Institute on Drug Abuse

International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional), PA-18-773, National Institutes of Health; National Institute on Drug Abuse

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional), PA-18-775, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional), PAR-18-746, National Institutes of Health; National Institute on Drug Abuse

Investigator-Initiated Genomic Medicine Research (R01 Clinical Trial Optional), PAR-18-735, National Institutes of Health; National Human Genome Research Institute

Investigator-Initiated Genomic Medicine Research (R21 Clinical Trial Optional), PAR-18-736, National Institutes of Health; National Human Genome Research Institute

Coordinating Center to Support NIDA Rural Opioid HIV and Comorbidity Initiative (U24 - Clinical Trial Not Allowed), RFA-DA-19-004, National Institutes of Health; National Institute on Drug Abuse

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01, Clinical Trial Optional), RFA-DA-18-022, National Institutes of Health; National Institute on Drug Abuse

Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment (R61/R33 Clinical Trial Required), RFA-DA-19-005, National Institutes of Health; National Institute on Drug Abuse

NIDA Small Research Grant Program (R03 Clinical Trial Required), PA-18-634, National Institutes of Health; National Institute on Drug Abuse

NIDA Small Research Grant Program (R03 Clinical Trial Required), PA-18-626, National Institutes of Health; National Institute on Drug Abuse

NIDA Academic Research Enhancement Award (R15, Clinical Trials Required), PA-18-627, National Institutes of Health; National Institute on Drug Abuse

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01, Clinical Trial Optional), PA-18-569, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

International Research Collaboration on Drug Abuse and Addiction Research (R01, Clinical Trial Optional), PA-18-568, National Institutes of Health; National Institute on Drug Abuse

Improving Implementation of Seek, Test, Treat and Retain Strategies among People Who Inject Drugs in Low to Middle Income Countries (R01-Clinical Trial Required), RFA-DA-18-017, National Institutes of Health; National Institute on Drug Abuse

Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (R01- Clinical Trial Not Allowed), RFA-DA-18-023, National Institutes of Health; National Institute on Drug Abuse

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03 Clinical Trial Optional), PAR-18-527, National Institutes of Health; National Institute on Drug Abuse

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 ), PAR-18-510, National Institutes of Health; National Institute on Drug Abuse

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21 Clinical Trial Optional ), PAR-18-509, National Institutes of Health; National Institute on Drug Abuse

Device-Based Treatments for Substance Use Disorders (UG3/UH3) (Clinical Trial Optional), PAR-18-494, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional), RFA-DA-19-002, National Institutes of Health; National Institute on Drug Abuse

Pilot Effectiveness Trials for Post-Acute Interventions and Serivces to Optimize Longer-Term Outcomes (R34-Clinical Trials Required), PAR-18-431, National Institutes of Health; National Institute of Mental Health

Effectiveness Trials for Post-Acute Interventions and Services and Services to Optimize Longer-Term Outcomes (R01-Clinical Trials Required), PAR-18-430, National Institutes of Health; National Institute of Mental Health

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3, Clinical Trial Optional), RFA-DA-18-020, National Institutes of Health; National Institute on Drug Abuse

NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional), RFA-DA-18-019, National Institutes of Health; National Institute on Drug Abuse

NIDA Core Center of Excellence Grant Program (P30 Clinical Trial Optional), PAR-18-225, National Institutes of Health; National Institute on Drug Abuse

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional), PAR-18-224, National Institutes of Health; National Institute on Drug Abuse

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional), PAR-18-226, National Institutes of Health; National Institute on Drug Abuse

NIDA Program Project Grant Applications (P01, Clinical Trial Optional), PAR-18-425, National Institutes of Health; National Institute on Drug Abuse

Fast-Track Development of Medications to Treat Cannabis Use Disorders (UG3/UH3 Clinical Trial Optional), PAR-18-221, National Institutes of Health; National Institute on Drug Abuse

Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required), PAR-18-233, National Institutes of Health; National Institute of Mental Health

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required), PAR-18-232, National Institutes of Health; National Institute of Mental Health

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional), PAR-18-219, National Institutes of Health; National Institute on Drug Abuse

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01 Clinical Trial Optional), PAR-18-218, National Institutes of Health; National Institute on Drug Abuse

Ancillary Studies to Identify Behavioral and/or Psychological Phenotypes Contributing to Obesity (R01 Clinical Trial Optional), PAR-18-105, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; Office of Behavioral and Social Sciences Research

Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional), RFA-OD-18-001, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-18-002, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Tobacco Regulatory Science (R21 Clinical Trial Optional), RFA-OD-18-003, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional), PAR-18-082, National Institutes of Health; National Institute on Drug Abuse

Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional), PAR-18-081, National Institutes of Health; National Institute on Drug Abuse; National Institute of Biomedical Imaging and Bioengineering

Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33), RFA-AT-18-002, National Institutes of Health; National Center for Complementary and Integrative Health

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional), PA-18-072, National Institutes of Health; National Institute on Drug Abuse

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 Clinical Trial Optional), PA-18-071, National Institutes of Health; National Institute on Drug Abuse

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21 Clinical Trial Optional), PA-18-070, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03 Clinical Trial Optional), PA-18-069, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34 Clinical Trial Optional), PA-18-068, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional), PA-18-067, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

International Research Collaboration on Drug Abuse and Addiction Research (R21 Clinical Trial Optional), PA-18-066, National Institutes of Health; National Institute on Drug Abuse

International Research Collaboration on Drug Abuse and Addiction Research (R03 Clinical Trial Optional), PA-18-065, National Institutes of Health; National Institute on Drug Abuse

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01- Clinical Trial Required), RFA-MH-18-707, National Institutes of Health; National Institute of Mental Health

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required), RFA-MH-18-706, National Institutes of Health; National Institute of Mental Health

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33- Clinical Trial Required), RFA-MH-18-705, National Institutes of Health; National Institute of Mental Health

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33- Clinical Trial Required), RFA-MH-18-704, National Institutes of Health; National Institute of Mental Health

Early Stage Testing of Pharmacologic or Device -based Interventions for the Treatment of Mental Health Disorders (R33- Clinical Trial Required), RFA-MH-18-703, National Institutes of Health; National Institute of Mental Health

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33-Clinical Trial Required), RFA-MH-18-702, National Institutes of Health; National Institute of Mental Health

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01- Clinical Trial Required), RFA-MH-18-701, National Institutes of Health; National Institute of Mental Health

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01-Clinical Trial Required), RFA-MH-18-700, National Institutes of Health; National Institute of Mental Health

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional), PAR-18-064, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute

Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional), PA-18-078, National Institutes of Health; National Institute on Drug Abuse

Neuroscience Research on Drug Abuse (R01 Clinical Trial Optional), PA-18-060, National Institutes of Health; National Institute on Drug Abuse

Prescription Drug Abuse (R21 Clinical Trial Optional), PA-18-076, National Institutes of Health; National Institute on Drug Abuse

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21 Clinical Trial Optional), PA-18-075, National Institutes of Health; National Institute on Drug Abuse

Behavioral and Integrative Treatment Development Program (R03 Clinical Trial Optional), PA-18-074, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), PA-18-073, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Prescription Drug Abuse (R01 Clinical Trial Optional), PA-18-058, National Institutes of Health; National Institute on Drug Abuse

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01 Clinical Trial Optional), PA-18-056, National Institutes of Health; National Institute on Drug Abuse

Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional), PA-18-055, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional), PAR-18-062, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism

The Application of Big Data Analytics to Drug Abuse Research (R01 Clinical Trial Optional), PA-18-057, National Institutes of Health; National Institute on Drug Abuse

Pharmacogenomics of Anti-retroviral Therapy in People Who Inject Drugs (R01), RFA-DA-18-014, National Institutes of Health; National Institute on Drug Abuse

Tobacco Regulatory Science Small Grant Program for New Investigators (R03), RFA-OD-17-012, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Tobacco Regulatory Science (R21), RFA-OD-17-014, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Tobacco Regulatory Science (R01), RFA-OD-17-013, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

The NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL) (U24), RFA-HG-17-011, National Institutes of Health; National Human Genome Research Institute

Limited Competition Cohort Studies of HIV/AIDS and Substance Abuse (U01), RFA-DA-18-011, National Institutes of Health; National Institute on Drug Abuse

HIV/HCV Co-Infections in Substance Abusers (R01), PAS-17-311, National Institutes of Health; National Institute on Drug Abuse

Addressing Suicide Research Gaps: Understanding Mortality Outcomes (R01), RFA-MH-18-410, National Institutes of Health; National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute on Drug Abuse; National Institue on Minority Health and Health Disparities

Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33), RFA-AT-18-001, National Institutes of Health; National Center for Complementary and Integrative Health

Tobacco Regulatory Science (R21), RFA-OD-17-009, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Tobacco Regulatory Science Small Grant Program for New Investigators (R03), RFA-OD-17-008, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Tobacco Regulatory Science (R01), RFA-OD-17-007, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Genomic Community Resources (U24), PAR-17-273, National Institutes of Health; National Human Genome Research Institute; National Cancer Institute

Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01), PAR-17-272, National Institutes of Health; National Institute of Mental Health

Pilot Effectivness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34), PAR-17-271, National Institutes of Health; National Institute of Mental Health

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (Collaborative R01), PAR-17-252, National Institutes of Health; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (R01), PAR-17-253, National Institutes of Health; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism

Expanding Medication Assisted Treatment for Opioid Use Disorders in the Context of the SAMHSA Opioid STR Grants (R21/R33), RFA-DA-18-005, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicles and Substance Use Disorders (R21), PAR-17-242, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicles and Substance Use Disorders (R01), PAR-17-250, National Institutes of Health; National Institute on Drug Abuse

Center for Coordination of Analytics, Science, Enhancement , and Logistics (CASEL) in Tobacco Regulatory Science (U54), RFA-OD-17-002, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Institute on Drug Abuse; U.S. Food and Drug Administration, Center for Tobacco P

Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54), RFA-OD-17-003, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3), RFA-DA-18-003, National Institutes of Health; National Institute on Drug Abuse

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (Collaborative U01), PAR-17-176, National Institutes of Health; National Institute of Mental Health

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (U01), PAR-17-179, National Institutes of Health; National Institute of Mental Health

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R21), PA-17-157, National Institutes of Health; National Institute on Drug Abuse

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R01), PA-17-155, National Institutes of Health; National Institute on Drug Abuse

Basic Mechanisms of Brain Development Mediating Substance Use and Dependence (R01), PA-17-119, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01), PA-17-120, National Institutes of Health; National Institute on Drug Abuse

Neuroscience Research on Drug Abuse (R21), PA-17-112, National Institutes of Health; National Institute on Drug Abuse

Neuroscience Research on Drug Abuse (R01), PA-17-111, National Institutes of Health; National Institute on Drug Abuse

NIDA Core Center of Excellence Grant Program (P30), PAR-17-121, National Institutes of Health; National Institute on Drug Abuse

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01), RFA-MH-17-614, National Institutes of Health; National Institute of Mental Health

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34), RFA-MH-17-612, National Institutes of Health; National Institute of Mental Health

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01), RFA-MH-17-610, National Institutes of Health; National Institute of Mental Health

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33), RFA-MH-17-602, National Institutes of Health; National Institute of Mental Health

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01), RFA-MH-17-608, National Institutes of Health; National Institute of Mental Health

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33), RFA-MH-17-604, National Institutes of Health; National Institute of Mental Health

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33), RFA-MH-17-606, National Institutes of Health; National Institute of Mental Health

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33), RFA-MH-17-600, National Institutes of Health; National Institute of Mental Health

NIH-DoD-VA Pain Management Collaboratory - Pragmatic Clinical Trials Demonstration Projects (UG3/UH3), RFA-AT-17-001, National Institutes of Health; Department of Defense; Department of Veterans Affairs; National Center for Complementary and Integrative Health; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health a

Hepatitis C Virus (HCV) Advanced Molecular Detection in Support of Systems for Prevention, Treatment and Control of HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States (U24), RFA-DA-17-023, National Institutes of Health; Centers for Disease Control and Prevention; National Institute on Drug Abuse; National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention

HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control (UG3/UH3), RFA-DA-17-014, National Institutes of Health; Centers for Disease Control and Prevention; Substance Abuse and Mental Health Services Administration; Appalachian Regional Commission; National Institute on Drug Abuse; National Center for HIV/AIDS, Viral Hepatitis, STD and

Drug Abuse Dissertation Research (R36), PA-16-443, National Institutes of Health; National Institute on Drug Abuse

Centers of Excellence in Genomic Science (CEGS) (RM1), PAR-16-436, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01), PAR-16-430, National Institutes of Health; National Institute on Drug Abuse

Grand Opportunity in Medications Development for Substance-Use Disorders (U01), PAR-16-431, National Institutes of Health; National Institute on Drug Abuse

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24), RFA-DA-17-019, National Institutes of Health; National Institute on Drug Abuse

NIDA Program Project Grant Applications (P01), PAR-16-393, National Institutes of Health; National Institute on Drug Abuse

Chemistry Science Track Award for Rapid Transition (C/START) (R03), PAR-16-383, National Institutes of Health; National Institute on Drug Abuse

Chemical Discovery (CHEM) Award (R21/R33), PAR-16-384, National Institutes of Health; National Institute on Drug Abuse

Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01), RFA-DA-17-013, National Institutes of Health; National Institute on Drug Abuse

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1), PAR-16-357, National Institutes of Health; National Institute on Drug Abuse

Ancillary Studies to Identify Behavioral and/or Psychological Phenotypes Contributing to Obesity (R01), PAR-16-304, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; Office of Behavioral and Social Sciences Research

Reducing the Duration of Untreated Psychosis in the United States (R01), PAR-16-265, National Institutes of Health; National Institute of Mental Health

Reducing the Duration of Untreated Psychosis in the United States (R34), PAR-16-264, National Institutes of Health; National Institute of Mental Health

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01), PAR-16-234, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism

Prescription Drug Abuse (R21), PA-16-232, National Institutes of Health; National Institute on Drug Abuse

Prescription Drug Abuse (R01), PA-16-233, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicle Tools, Technologies, and Products for Neuroscience Research (R41/R42), RFA-DA-17-008, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicle Tools, Technologies, and Products for Neuroscience Research (R43/R44), RFA-DA-17-009, National Institutes of Health; National Institute on Drug Abuse

Role of Astrocytes and Astrocytic Networks in Drug Abuse (R21), PA-16-145, National Institutes of Health; National Institute on Drug Abuse

Role of Astrocytes and Astrocytic Networks in Drug Abuse (R01), PA-16-144, National Institutes of Health; National Institute on Drug Abuse

The Application of Big Data Analytics to Drug Abuse Research (R01), PA-16-119, National Institutes of Health; National Institute on Drug Abuse

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3), RFA-DA-17-015, National Institutes of Health; National Institute on Drug Abuse

Services Planning Research in the Appalachian Region to Address Adverse Health Consequences Associated with Increased Opioid Injection Drug Use (R03), RFA-DA-16-015, National Institutes of Health; Appalachian Regional Commission; National Institute on Drug Abuse

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21), PA-16-075, National Institutes of Health; National Institute on Drug Abuse

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01), PA-16-076, National Institutes of Health; National Institute on Drug Abuse

Behavioral and Integrative Treatment Development Program (R03), PA-16-074, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Behavioral and Integrative Treatment Development Program (R01), PA-16-072, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Behavioral and Integrative Treatment Development Program (R34), PA-16-073, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Behavioral Science Track Award for Rapid Transition (B/Start)(R03), PAR-16-071, National Institutes of Health; National Institute on Drug Abuse

Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01), RFA-DA-16-012, National Institutes of Health; National Institute on Drug Abuse

Systems Biology Approaches in HIV/AIDS and Substance Use (R01), RFA-DA-16-013, National Institutes of Health; National Institute on Drug Abuse

Mechanism for Time-Sensitive Drug Abuse Research (R21), PAR-16-055, National Institutes of Health; National Institute on Drug Abuse

Seek, Test, Treat and Retain For Youth and Young Adults Living with or at High Risk for Acquiring HIV (R01), RFA-DA-16-010, National Institutes of Health; National Institute on Drug Abuse

Effects of Drugs of Abuse on Latent HIV Reservoirs in the CNS (R01), RFA-DA-16-014, National Institutes of Health; National Institute on Drug Abuse

Integration of Infectious Diseases and Substance Abuse Intervention Services for Individuals Living with HIV (R01), RFA-DA-16-011, National Institutes of Health; National Institute on Drug Abuse

Environmental Influences on Child Health Outcomes: Patient Reported Outcomes Research Resource Center Core (ECHO PRO Core) (U24), RFA-OD-16-003, National Institutes of Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Nationa

Environmental Influences on Child Health Outcomes (ECHO) Pediatric Cohorts (UG3/UH3), RFA-OD-16-004, National Institutes of Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Nationa

NIDA Research Center of Excellence Grant Program (P50), PAR-16-009, National Institutes of Health; National Institute on Drug Abuse

Major Opportunities for Research in Epidemiology of Alzheimer's Disease and Cognitive Resilience (R01), PAR-15-356, National Institutes of Health; National Institute on Aging

AIDS-Science Track Award for Research Transition (R03), PA-15-290, National Institutes of Health; National Institute on Drug Abuse

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3), RFA-DA-16-008, National Institutes of Health; National Institute on Drug Abuse

Imaging - Science Track Award for Research Transition (I/START) (R03), PAR-15-326, National Institutes of Health; National Institute on Drug Abuse; National Institute of Biomedical Imaging and Bioengineering

Tools for Monitoring and Manipulating Modified RNAs in the Nervous System (R43/R44), RFA-DA-16-005, National Institutes of Health; National Institute on Drug Abuse

Tools for Monitoring and Manipulating Modified RNAs in the Nervous System (R41/R42), RFA-DA-16-006, National Institutes of Health; National Institute on Drug Abuse

Data Coordinating Center for Sickle Cell Disease Implementation Consortium (SCDIC): Using Implementation Science to Optimize Care of Adolescents and Adults with Sickle Cell Disease (U24), RFA-HL-16-011, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Minority Health and Health Disparities

Extracellular Vesicles and Substance Abuse (R21), PAR-15-284, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicles and Substance Abuse (R01), PAR-15-283, National Institutes of Health; National Institute on Drug Abuse

Longitudinal Assessment of Post -traumatic Syndromes (U01), RFA-MH-16-500, National Institutes of Health; National Institute of Mental Health

Tools and Services for Designing Methodologically Rigorous Animal Studies (R41/R42), RFA-DA-16-002, National Institutes of Health; National Institute on Drug Abuse

Tools and Services for Designing Methodologically Rigorous Animal Studies (R43/R44), RFA-DA-16-003, National Institutes of Health; National Institute on Drug Abuse

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34), PA-15-268, National Institutes of Health; National Institute on Drug Abuse; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health

Harnessing Genome Editing Technologies to Functionally Validate Genetic Variants in Substance Use Disorders (R21/R33), RFA-DA-16-004, National Institutes of Health; National Institute on Drug Abuse

Fast-Track Development of Medications to Treat Cannabis Use Disorders (UG3/UH3), PAR-15-267, National Institutes of Health; National Institute on Drug Abuse

Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R61/R33), RFA-MH-16-406, National Institutes of Health; National Institute of Mental Health

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03), PA-15-252, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34), PA-15-250, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01), PA-15-251, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34), PA-15-250, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21), PA-15-253, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34), PA-15-177, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Clinical Trials to Test the Effectiveness of Treatment, Preventive and Services Interventions (Collaborative R01), RFA-MH-16-415, National Institutes of Health; National Institute of Mental Health

Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R33), RFA-MH-16-400, National Institutes of Health; National Institute of Mental Health

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01), RFA-MH-16-420, National Institutes of Health; National Institute of Mental Health

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01), RFA-MH-16-425, National Institutes of Health; National Institute of Mental Health

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34), RFA-MH-16-410, National Institutes of Health; National Institute of Mental Health

International Research Collaboration on Drug Abuse and Addiction Research (R21), PA-15-143, National Institutes of Health; National Institute on Drug Abuse

International Research Collaboration on Drug Abuse and Addiction Research (R01), PA-15-142, National Institutes of Health; National Institute on Drug Abuse

International Research Collaboration on Drug Abuse and Addiction Research (R03), PA-15-141, National Institutes of Health; National Institute on Drug Abuse

Identification of Genetic and Genomic Variants by Next-Gen in Sequencing Non-human Animal Models (U01), PAR-15-120, National Institutes of Health; National Institute on Drug Abuse

NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12), PAR-15-119, National Institutes of Health; National Institute on Drug Abuse

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01), RFA-DA-16-001, National Institutes of Health; National Institute on Drug Abuse

Gene-Environment Interplay in Substance Use Disorders (R21), PA-15-112, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Gene-Environment Interplay in Substance Use Disorders (R03), PA-15-111, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Gene-Environment Interplay in Substance Use Disorders (R01), PA-15-110, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis and Informatics Center (U24), RFA-DA-15-016, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Adolescent Brain Cognitive Development (ABCD) Study - Research Project Sites (U01), RFA-DA-15-015, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Adolescent Brain Cognitive Development (ABCD) Study - Coordinating Center (U24), RFA-DA-15-014, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Reductions in Illicit Drug Use and Functional Outcomes (R21/R33), PA-15-099, National Institutes of Health; National Institute on Drug Abuse

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3), RFA-DA-15-017, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Prevention Intervention Research (R21), PA-15-080, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Prevention Intervention Research (R03), PA-15-081, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Prevention Intervention Research (R01), PA-15-082, National Institutes of Health; National Institute on Drug Abuse

Identification of Genetic and Genomic Variants by Next-Gen in Sequencing Non-human Animal Models (U01), PAR-15-120, National Institutes of Health; National Institute on Drug Abuse

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01), RFA-DA-16-001, National Institutes of Health; National Institute on Drug Abuse

Gene-Environment Interplay in Substance Use Disorders (R21), PA-15-112, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Gene-Environment Interplay in Substance Use Disorders (R03), PA-15-111, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis and Informatics Center (U24), RFA-DA-15-016, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Reductions in Illicit Drug Use and Functional Outcomes (R21/R33), PA-15-099, National Institutes of Health; National Institute on Drug Abuse

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3), RFA-DA-15-017, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Prevention Intervention Research (R01), PA-15-082, National Institutes of Health; National Institute on Drug Abuse

Children's Health Exposure Analysis Resource (CHEAR): Coordinating Center (U24), RFA-ES-15-011, National Institutes of Health; National Institute of Environmental Health Sciences

Epidemiology of Drug Abuse (R21), PA-15-001, National Institutes of Health; National Institute on Drug Abuse

Epidemiology of Drug Abuse (R03), PA-15-002, National Institutes of Health; National Institute on Drug Abuse

Epidemiology of Drug Abuse (R01), PA-15-003, National Institutes of Health; National Institute on Drug Abuse

Enhancing Cross-National Research within the Health and Retirement Study Family of Studies (R01), RFA-AG-15-015, National Institutes of Health; National Institute on Aging

Interventions for Youth who Misuse/Abuse Prescription Stimulant Medications in High School and/or College-Attending Youth (U01), RFA-DA-15-010, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicles in HIV/AIDS and Substance Abuse (R21), RFA-DA-15-012, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicles in HIV/AIDS and Substance Abuse (R01), RFA-DA-15-011, National Institutes of Health; National Institute on Drug Abuse

The National Drug Abuse Treatment Clinical Trials Network (UG1), RFA-DA-15-008, National Institutes of Health; National Institute on Drug Abuse

Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R33), PAR-14-231, National Institutes of Health; National Institute on Drug Abuse; National Institute of Mental Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism

Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R21/R33), PAR-14-230, National Institutes of Health; National Institute on Drug Abuse; National Institute of Mental Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism

Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01), PAR-14-225, National Institutes of Health; National Institute on Drug Abuse; National Center for Complementary and Integrative Health; National Cancer Institute

Long-Term Retention in Care for U.S. Substance Using Populations (R01), PA-14-224, National Institutes of Health; National Institute on Drug Abuse

Long-Term Retention in Care for U.S. Substance Using Populations (R21), PA-14-223, National Institutes of Health; National Institute on Drug Abuse

Long-Term Retention in Care for U.S. Substance Using Populations (R34), PA-14-222, National Institutes of Health; National Institute on Drug Abuse

Centers of Excellence in Genomic Science (CEGS) (RM1), PAR-14-195, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health

Epidemiology and Prevention in Alcohol Research (R01), PA-14-190, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism

Epidemiology and Prevention in Alcohol Research (R03), PA-14-189, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism

Epidemiology and Prevention in Alcohol Research (R21), PA-14-188, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism

Genomic Resource Grants for Community Resource Projects (U41), PAR-14-191, National Institutes of Health; National Cancer Institute; National Human Genome Research Institute

NIDA Core Center of Excellence Grant Program (P30), PAR-14-186, National Institutes of Health; National Institute on Drug Abuse

Effects of Cannabis Use and Cannabinoids on the Developing Brain (R01), PA-14-163, National Institutes of Health; National Institute on Drug Abuse

Effects of Cannabis Use and Cannabinoids on the Developing Brain (R21), PA-14-162, National Institutes of Health; National Institute on Drug Abuse

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01), PA-14-137, National Institutes of Health; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney Diseases

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21), PA-14-136, National Institutes of Health; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney Diseases

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34), PA-14-135, National Institutes of Health; National Institute on Drug Abuse

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01), PAR-14-106, National Institutes of Health; National Institute on Drug Abuse

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21), PAR-14-105, National Institutes of Health; National ?Institute on Drug Abuse

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03), PAR-14-104, National Institutes of Health; National Institute on Drug Abuse

NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1), RFA-DA-15-004, National Institutes of Health; National Institute on Drug Abuse

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01), RFA-DA-15-005, National Institutes of Health; National Institute on Drug Abuse

Neuroimmune Signaling in Substance Use Disorders (R01), PA-14-084, National Institutes of Health; National Institute on Drug Abuse

Neuroimmune Signaling and Function in Substance Use Disorders (R21), PA-14-083, National Institutes of Health; National Institute on Drug Abuse

Medications Development Centers of Excellence Cooperative Program (U54), RFA-DA-15-003, National Institutes of Health; National Institute on Drug Abuse

Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R01), PA-14-061, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R21), PA-14-062, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R03), PA-14-063, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R21), PA-14-036, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03), PA-14-037, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R01), PA-14-038, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Basic Mechanisms of Brain Development for Substance Use and Dependence (R01), PA-14-026, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01), PA-14-025, National Institutes of Health; National Institute on Drug Abuse

Public Health Impact of the Changing Policy/Legal Environment for Marijuana (R01), PAS-14-020, National Institutes of Health; National Institute on Drug Abuse

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Abuse (R21), PA-14-013, National Institutes of Health; National Institute on Drug Abuse

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Abuse (R01), PA-14-014, National Institutes of Health; National Institute on Drug Abuse

Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM) (R21/R33), PAR-13-350, National Institutes of Health; National Institute on Drug Abuse

Neuroscience Research on Drug Abuse (R03), PA-13-336, National Institutes of Health; National Institute on Drug Abuse

Neuroscience Research on Drug Abuse (R21), PA-13-337, National Institutes of Health; National Institute on Drug Abuse

Neuroscience Research on Drug Abuse (R01), PA-13-338, National Institutes of Health; National Institute on Drug Abuse

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01), PAR-13-334, National Institutes of Health; National Institute on Drug Abuse

Administrative Supplements to Promote Collaborative Research on Addiction at NIH (CRAN): Comorbidity-Related Research (Admin Supp), PA-13-275, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism

Grand Opportunity in Medications Development for Substance-Use Disorders (U01), PAR-13-270, National Institutes of Health; National Institute on Drug Abuse

Seek, Test, Treat, and Retain Data Harmonization Coordinating Center (U01), RFA-DA-14-007, National Institutes of Health; National Institute on Drug Abuse

FY14 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1), RFA-DA-14-008, National Institutes of Health; National Institute on Drug Abuse

NIDA Research Center of Excellence Grant Program (P50), PAR-13-222, National Institutes of Health; National Institute on Drug Abuse

Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R01), RFA-DA-14-005, National Institutes of Health; National Institute on Drug Abuse

Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R21), RFA-DA-14-006, National Institutes of Health; National Institute on Drug Abuse

Medications Development Centers of Excellence Cooperative Program (U54), RFA-DA-14-004, National Institutes of Health; National Institute on Drug Abuse

Centers of Excellence in Genomic Science (CEGS) (P50), PAR-13-198, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health

Drug Abuse Dissertation Research (R36), PAR-13-182, National Institutes of Health; National Institute on Drug Abuse

Revision Applications to Promote Collaborative Research on Addiction at NIH (CRAN): Comorbidity-Related Research (R01), RFA-DA-14-014, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism

NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12), PAR-13-163, National Institutes of Health; National Institute on Drug Abuse

Prevention and Health Promotion Interventions to Prevent Alcohol and Other Drug Abuse and Associated Physical and Psychological Health Problems in U.S. Military Personnel, Veterans and their Families (R01), RFA-DA-13-012, National Institutes of Health; The Department of Defense; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of the Assistant Secretary of Defense for Health Affairs

Prevention and Health Promotion Interventions to Prevent Alcohol and Other Drug Abuse and Associated Physical and Psychological Health Problems in U.S. Military Personnel, Veterans and their Families (R34), RFA-DA-13-013, National Institutes of Health; The Department of Defense; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Center for Complementary and Alternative Medicine; Office of the Assistant Secretary of Defense for He

Behavioral & Integrative Treatment Development Program (R01), PA-13-077, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Center for Complementary and Integrative Health

Behavioral & Integrative Treatment Development Program (R34), PA-13-078, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Behavioral & Integrative Treatment Development Program (R03), PA-13-079, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01), PAR-13-080, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute

Prescription Drug Abuse (R01), PA-13-015, National Institutes of Health; National Institute on Drug Abuse

Prescription Drug Abuse(R21), PA-13-016, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Aspects of HIV/AIDS (R01), PA-12-293, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Aspects of HIV/AIDS (R03), PA-12-294, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Aspects of HIV/AIDS (R21), PA-12-295, National Institutes of Health; National Institute on Drug Abuse

HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21), PA-12-280, National Institutes of Health; National Institute on Drug Abuse

HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R01), PA-12-281, National Institutes of Health; National Institute on Drug Abuse

Human Heredity and Health in Africa (H3Africa): Collaborative Centers (U54), RFA-RM-12-006, National Institutes of Health; This Funding Opportunity Announcement; Division of Program Coordination, Planning and Strategic Initiatives; Office of Strategic Coordination; National Human Genome Research Institute; Eunice Kennedy Shriver National Institu

Human Heredity and Health in Africa (H3Africa): H3Africa Research Grants (U01), RFA-RM-12-007, National Institutes of Health; This Funding Opportunity Announcement; Division of Program Coordination, Planning and Strategic Initiatives; Office of Strategic Coordination; National Human Genome Research Institute; Eunice Kennedy Shriver National Institu

Behavioral Science Track Award for Rapid Transition (B/START) (R03), PAR-12-251, National Institutes of Health; National Institute on Drug Abuse

Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21), PAR-12-238, National Institutes of Health; National Institute on Drug Abuse

Human Heredity and Health in Africa (H3Africa): H3Africa Research Grants (U01), PAR-12-239, National Institutes of Health; This Funding Opportunity Announcement; Division of Program Coordination, Planning and Strategic Initiatives; Office of Strategic Coordination; National Human Genome Research Institute; Eunice Kennedy Shriver National Institu

Cohort Studies of HIV/AIDS and Substance Use (U01), PAR-12-222, National Institutes of Health; National Institute on Drug Abuse

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34), PA-12-231, National Institutes of Health; National Institute on Drug Abuse

Research Education Grants for Statistical and Computational Training in the Genetics of Addiction (R25), PAR-12-199, National Institutes of Health; National Institute on Drug Abuse

Small Grants for Behavioral Research in Cancer Control (R03), PAR-12-035, National Institutes of Health; National Cancer Institute

Gene-Environment Interplay in Substance Use Disorders (R21), PA-11-236, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Gene-Environment Interplay in Substance Use Disorders (R03), PA-11-237, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Gene-Environment Interplay in Substance Use Disorders (R01), PA-11-235, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Personalized Genomics for Symptom Management: Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R01), RFA-NR-11-003, National Institutes of Health; National Institute of Nursing Research

Personalized Genomics for Symptom Management: Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R21), RFA-NR-11-004, National Institutes of Health; National Institute of Nursing Research

The Electronic Medical Records and Genomics (eMERGE) Network, Phase II Coordinating Center (U01), RFA-HG-10-010, National Institutes of Health; National Human Genome Research Institute; The Electronic Medical Records and Genomics

Pharmacogenomics Research Network (U01/U19), RFA-GM-10-001, National Institutes of Health; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institute on Drug Abuse; National Institute on Mental Health; National Institute of Child Health

Genome-wide Association Studies of Treatment Response in Randomized Clinical Trials-Study Investigators (U01), RFA-HG-08-004, National Institutes of Health; National Human Genome Research Institute

Genome-wide Association Studies of Treatment Response in Randomized Clinical Trials - Coordinating Center (U01), RFA-HG-08-005, National Institutes of Health; National Human Genome Research Institute

Limited Competition: NIMHD Initiative for Improving American Indian and Alaska Native Cancer Outcomes (U19 - Clinical Trial Optional), RFA-MD-24-009, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)

Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 - Clinical Trial Optional), PAR-24-231, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)

Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions (P50 Clinical Trial Optional), RFA-HD-25-002, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS)

Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional), PAR-24-207, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI)

Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Optional), RFA-MH-25-185, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), Office of AIDS Research (OAR), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute on Minority Health and Health Disparities (NIMHD)

Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional), RFA-MH-25-186, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), Office of AIDS Research (OAR), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Drug Abuse (NIDA)

Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional), PAR-24-110, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Cancer Institute (NCI), Office of Behavioral and Social Sciences Research (OBSSR)

Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical Trial Required), RFA-MH-25-130, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional), RFA-MH-25-190, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed), PAR-24-162, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities (R01 - Clinical Trials Not Allowed), RFA-MD-24-005, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Sexual and Gender Minority Research Office (SGMRO)

Translational Neural Devices (R61/R33 - Clinical Trial Optional), PAR-24-151, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

Limited Competition: Collaborative Study on the Genetics of Alcoholism (COGA) (U10 Clinical Trial Not Allowed), RFA-AA-24-003, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional), PAR-24-118, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA)

High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional), RFA-DA-25-060, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional), PAR-23-318, National Institutes of Health (NIH), Fogarty International Center (FIC), National Eye Institute (NEI), National Background Investigation Bureau, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Mental Health (NIMH), National Cancer Institute (NCI), Office of Dietary Supplements (ODS), Office of Research on Women's Health (ORWH)

Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional), PAR-24-077, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Office of Behavioral and Social Sciences Research (OBSSR), Sexual and Gender Minority Research Office (SGMRO)

Coordinating Center to Support Multi-Sectoral Preventive Interventions that Address Social Determinants of Health in Populations that Experience Health Disparities (U24, Clinical Trial Not Allowed), RFA-OD-24-006, National Institutes of Health (NIH), Office of Disease Prevention (ODP), National Institute on Minority Health and Health Disparities (NIMHD), Office of Data Science Strategy (ODSS)

Multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities (UG3/UH3, Clinical Trial Required), PAR-24-053, National Institutes of Health (NIH), Office of Disease Prevention (ODP), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), Office of Dietary Supplements (ODS), Sexual and Gender Minority Research Office (SGMRO), Office of Research on Women's Health (ORWH)

The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required), RFA-DA-25-027, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional), PAR-24-067, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional), PAR-24-068, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Advancing Genomic Medicine Research (R01 Clinical Trial Optional), RFA-HG-23-032, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI)

Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed), RFA-HG-23-048, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)

Advancing Genomic Medicine Research (R21 Clinical Trial Optional), RFA-HG-23-033, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI)

Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional), PAR-23-293, National Institutes of Health (NIH), Fogarty International Center (FIC), National Human Genome Research Institute (NHGRI), National Eye Institute (NEI), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI), National Institute on Minority Health and Health Disparities (NIMHD), Office of Research on Women's Health (ORWH)

Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional), PAR-23-295, National Institutes of Health (NIH), Fogarty International Center (FIC), National Human Genome Research Institute (NHGRI), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Cancer Institute (NCI), Office of Data Science Strategy (ODSS), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women's Health (ORWH)

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional), PAR-23-294, National Institutes of Health (NIH), Fogarty International Center (FIC), National Human Genome Research Institute (NHGRI), National Eye Institute (NEI), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women's Health (ORWH)

Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional), PAR-24-059, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), Office of Disease Prevention (ODP), Office of Research on Women's Health (ORWH)

Comprehensive Alcohol-HIV/AIDS Research Center (P60 Clinical Trial Optional), RFA-AA-23-004, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required), RFA-MD-24-003, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), Sexual and Gender Minority Research Office (SGMRO), Office of Research on Women's Health (ORWH)

HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R01 Clinical Trial Optional), RFA-AA-23-005, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R34 Clinical Trial Optional), RFA-AA-23-006, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional), RFA-MD-24-001, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional), RFA-NS-24-021, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Career Enhancement Award to Advance the Study of Intimate Partner Violence (IPV) in the Context of Maternal Morbidity and Mortality Research (K18 Clinical Trial Not Allowed), RFA-OD-24-001, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Nursing Research (NINR), Sexual and Gender Minority Research Office (SGMRO), Office of Disease Prevention (ODP), Office of Research on Women's Health (ORWH)

Community-Engaged Health Equity Research in Neuroscience Initiative (R34 CT Not Allowed), RFA-NS-24-007, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

Community-Engaged Health Equity Research in Neuroscience Initiative (R01 CT Not Allowed), RFA-NS-24-006, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

Public Health Communication Messaging about the Continuum of Risk for Tobacco Products (U01 Clinical Trial Required), RFA-OD-23-021, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Office of Disease Prevention (ODP), National Cancer Institute (NCI)

Network of Genomics-Enabled Learning Health Systems (gLHS) - Coordinating Center (U01 Clinical Trials Required), RFA-HG-23-042, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)

Network of Genomics-Enabled Learning Health Systems (gLHS) - Clinical Sites (U01 Clinical Trial Required), RFA-HG-23-041, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)

HEAL Initiative: Toward Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required), RFA-AT-24-003, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)

Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional), RFA-HG-23-017, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Cancer Institute (NCI)

Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional), RFA-HG-23-018, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA)

Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional), RFA-MH-24-120, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors – Clinical Centers (U01 Clinical Trial Not Allowed), RFA-DK-23-010, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-23-017, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Cancer Institute (NCI)

Emergency Award: RADx-®UP Dissemination and Implementation (D&I) Research on COVID-19 Testing Interventions among Underserved and Vulnerable Populations (R01 Clinical Trial Optional), RFA-OD-23-051, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional), RFA-NS-23-028, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed), RFA-TR-23-011, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Advancing Integrated Models (AIM) of Care to Improve Pregnancy Outcomes among Women Who Experience Persistent Disparities (R01 Clinical Trial Optional), RFA-NR-23-002, National Institutes of Health (NIH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 - Clinical Trial Optional), RFA-MD-23-004, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)

Pilot Interventions to Integrate Social Care and Medical Care to Improve Health Equity (R01 Clinical Trial Required), RFA-DK-22-038, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required), PAR-23-090, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional), RFA-DA-24-037, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Career Enhancement Award to Advance Research on Firearm Injury and Mortality Prevention (K18 Independent Clinical Trial Not Allowed), PAR-23-108, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)

Career Enhancement Award to Advance Research on Firearm Injury and Mortality Prevention (K18 Independent Clinical Trial Required), PAR-23-107, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)

Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 – Clinical Trial Optional), PAR-23-112, National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Minority Health and Health Disparities (NIMHD), National Eye Institute (NEI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH)

Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required), RFA-MH-23-170, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

NIDA Program Project Grant Applications (P01 Clinical Trial Optional), PAR-23-064, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required), RFA-NS-23-012, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), Office of The Director, National Institutes of Health (OD)

Research Centers in Minority Institutions (RCMI) (U54 Clinical Trial Optional), RFA-MD-23-001, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)

Research on Community Level Interventions for Firearm and Related Violence, Injury and Mortality Prevention (CLIF-VP) (UG3/UH3 Clinical Trial Required), PAR-23-066, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), Sexual and Gender Minority Research Office (SGMRO)

Interventions that Address Structural Racism to Reduce Kidney Health Disparities - Research Coordinating Center (U24 - Clinical Trial Not Allowed), RFA-DK-23-003, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional), RFA-DA-23-059, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI)

HEAL Initiative - Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program: Leadership and Data Co-ordinating Center (U01 Clinical Trial Optional), RFA-DA-23-060, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI)

Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed), RFA-DA-24-002, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required), RFA-OD-22-026, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed), RFA-OD-22-025, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required), RFA-OD-22-024, , National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed), RFA-OD-22-023, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain (RM1 Clinical Trial Optional), RFA-NS-22-069, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Community Partnerships to Advance Science for Society (ComPASS): Coordination Center (U24 Clinical Trial Optional), RFA-RM-23-001, National Institutes of Health (NIH), Office of Strategic Coordination (Common Fund)

Advancing Adolescent Tobacco Cessation Intervention Research (R34 Clinical Trial Optional), RFA-CA-22-042, National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA)

Advancing Adolescent Tobacco Cessation Intervention Research (R01 Clinical Trial Required), RFA-CA-22-043, National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional), RFA-DA-23-061, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional), RFA-DA-23-062, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: HEAL Data2Action – Acceleration Projects (R33 Clinical Trial Not Allowed), RFA-DA-23-058, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards (R61/R33, Clinical Trial Optional), RFA-DA-23-057, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Prevention and Management of Chronic Pain in Rural Populations (UG3/UH3, Clinical Trials Required), RFA-NR-23-001, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health Sciences (NIEHS), National Cancer Institute (NCI), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI)

Limited Competition: The NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL) (U24 Clinical Trial Not Allowed), RFA-HG-22-020, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional), PAR-22-202, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)National Institute on Drug Abuse (NIDA)

Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional), PAR-22-200, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Environmental influences on Child Health Outcomes (ECHO) Data Analysis Center (U24 Clinical Trial Not Allowed), RFA-OD-22-022, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS)

Environmental influences on Child Health Outcomes (ECHO) Measurement Core (U24 Clinical Trial Not Allowed), RFA-OD-22-020, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS)

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R21 Basic Experimental Studies with Humans Required), RFA-HD-23-033, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R21 Clinical Trial Not Allowed), RFA-HD-23-031, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Clinical Trial Not Allowed), RFA-HD-23-030, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Basic Experimental Studies with Humans Required), RFA-HD-23-032, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed), RFA-EB-22-002, National Institutes of Health (NIH), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Development and validation of virtual assessments to study children and caregivers in their natural environment (R01- Clinical Trial Not Allowed), RFA-DA-23-050, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Development and validation of virtual assessments to study children and caregivers in their natural environment (R01- Basic Experimental Studies with Humans Required), RFA-DA-23-055, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)

Maternal Health Research Centers of Excellence Data Innovation and Coordinating Hub/Resource Center (U24 Clinical Trial Not Allowed), RFA-HD-23-036, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Office of AIDS Research (OAR), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), Sexual and Gender Minority Research Office (SGMRO)

AD/ADRD, Adverse Childhood Experiences, and Social Determinants of Health Ancillary Studies of Existing Longitudinal Cohorts (R01 - Clinical Trial Not Allowed), PAR-22-221, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA)

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional), RFA-DA-23-032, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional), RFA-DA-23-031, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional), RFA-DA-23-029, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional), RFA-DA-23-028, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional), RFA-DA-23-026, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Coordination Center to Support Racial Equity and Substance Use Disparities Research (U24 Clinical Trial Not Allowed), RFA-DA-23-025, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional), RFA-DA-23-024, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional), RFA-DA-23-023, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional), RFA-DA-23-013, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain (R01 Clinical Trial Not Allowed), RFA-NS-22-070, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Oral Complications Arising from Pharmacotherapies to Treat Opioid Use Disorders (R21 Clinical Trial Not Allowed), RFA-DE-23-016, National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Oral Complications Arising from Pharmacotherapies to Treat Opioid Use Disorders (R01 Clinical Trial Not Allowed), RFA-DE-23-015, National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional), RFA-DA-23-054, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional), RFA-DA-23-053, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional), RFA-NS-23-003, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Interventions that Address Structural Racism to Reduce Kidney Health Disparities - (U01 - Clinical Trial Required), RFA-DK-22-014, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

Interventions that Address Structural Racism to Reduce Kidney Health Disparities - Research Coordinating Center (U24 - Clinical Trial Not Allowed), RFA-DK-22-015, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Research Studies to Develop and Implement Interventions to Prevent Opioid Misuse in Community Health Centers (R61/R33 Clinical Trial Required), RFA-DA-23-048, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

NIH HEAL Initiative: Coordinated Approaches to Pain Care in Health Care Systems (UG3/UH3 - Clinical Trial Optional), RFA-NS-22-053, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Coordinated Pain Care in Health Care Systems Research Program - Coordinating Center (U24 Clinical Trial Not Allowed), RFA-NS-22-065, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH)

Expanding Collaborative Implementation Science to Address Social and Structural Determinants of Health and Improve HIV Outcomes (R01 Clinical Trial Required), RFA-MH-22-190, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA)

Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional), PAR-22-210, National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required), PAS-22-206, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required), PAS-22-207, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required), RFA-AT-23-002, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Advancing Translational Sciences (NCATS)

HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional), RFA-AT-23-001, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 - Clinical Trials Optional), RFA-DA-23-051, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Understanding the Pathophysiology and Clinical Course of New-Onset Diabetes Following COVID-19 (U01 Clinical Trial Not Allowed), RFA-DK-22-016, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL) (R01 Clinical Trial Required), RFA-DA-23-041, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL): Resource Center (U24- Clinical Trial Optional), RFA-DA-23-042, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH)

New Epidemiological Cohort Study among Asian Americans, Native Hawaiians, and Pacific Islanders (AsA-NHPI): Clinical/Community Field Centers (UG3/UH3 - Clinical Trial Not Allowed), RFA-HL-23-015, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH)

HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed), RFA-DA-23-045, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On (RM1 - Clinical Trial Optional), RFA-DA-23-046, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)

Enabling SUD Digital Therapeutics Research to Improve Payor Adoption (R44- Clinical Trial Only), RFA-DA-23-018, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA Program Project Grant Applications (P01 Clinical Trial Optional), PAR-22-201, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed), RFA-DA-23-017, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed), RFA-DA-23-052, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional), RFA-DA-23-020, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional), RFA-DA-23-019, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Stakeholder Engagement Innovation Center for Advancing Health Equity in Type 2 Diabetes Research (U2C - Clinical Trial Not Allowed), RFA-DK-22-001, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data Management Coordinating Center for Diagnostic Centers of Excellence (U2C Clinical Trial Not Allowed), RFA-NS-22-051, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Human Genome Research Institute (NHGRI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Research Coordinating Center to Support Climate Change and Health Community of Practice (U24 - Clinical Trial Not Allowed), RFA-ES-22-003, National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), Fogarty International Center (FIC), National Cancer Institute (NCI)

NINDS Interdisciplinary Team Science Grant (RM1 Clinical Trial Optional), RFA-NS-22-036, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required), RFA-NS-22-071, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), Office of The Director, National Institutes of Health (OD)

Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional), PAR-22-182, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional), PAR-22-183, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional), PAR-22-167, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of General Medical Sciences (NIGMS), National Institute on Minority Health and Health Disparities (NIMHD)

Emergency Awards: HEAL Initiative: Coordinating Center for National Pain Scientists Career Development (R24 Clinical Trial Not Allowed), RFA-NS-22-060, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH)

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed), RFA-DA-23-040, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed), RFA-NS-22-052, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Small Research Grants for Analysis, Curation, and/or Sharing of Down syndrome-related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed), RFA-OD-22-008, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)

Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required), RFA-DA-23-002, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trial Required), RFA-OD-22-010, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)

Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed), RFA-OD-22-009, National Institutes of Health (NIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)

INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed), RFA-OD-22-007, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)

Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional), PAR-22-145, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Mental Health (NIMH), National Library of Medicine (NLM)

Implementation Research to Reduce Noncommunicable Disease (NCD) Burden in Low- and Middle-Income Countries (LMICs) and Tribal Nations During Critical Life Stages and Key Transition Periods (R01 Clinical Trial Optional), PAR-22-132, National Institutes of Health (NIH), Fogarty International Center (FIC), National Eye Institute (NEI), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI)

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional), RFA-DA-23-021, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional), RFA-MD-22-008, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI)

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed), PAR-22-138, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD)

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed), PAR-22-137, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD)

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional), PAR-22-133, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R21 - Clinical Trial Not Allowed), RFA-DA-23-009, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R34 - Clinical Trial Optional), RFA-DA-23-010, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Addressing Mental Health Disparities Research Gaps: Aggregating and Mining Existing Data Sets for Secondary Analyses (R01 Clinical Trial Not Allowed), RFA-MH-22-200, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54 Clinical Trial Optional), RFA-OD-22-004, National Institutes of Health (NIH), , U.S. Food and Drug Administration (FDA), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS)

Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54 Clinical Trial Not Allowed), RFA-OD-22-003, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA)

Research on Community Level Interventions for Firearm and Related Violence, Injury and Mortality Prevention (CLIF-VP) (UG3/UH3 Clinical Trial Optional), PAR-22-115, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)

Coordinating Center to Support Research on Community Level Interventions for Firearm and Related Violence, Injury and Mortality Prevention (CLIF-VP) (U24 Clinical Trial Not Allowed), PAR-22-120, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)

Limited Competition for the Continuation of the Data Coordinating Center for the Diabetic Foot Consortium (U24 Clinical Trial Optional), RFA-DK-21-505, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R01 Clinical Trial Required), RFA-DA-23-006, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R34 Clinical Trial Required), RFA-DA-23-007, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Emergency Awards: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trial Optional), RFA-OD-22-005, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

Emergency Award: RADx-UP Community-Engaged Research on Rapid SARS-CoV-2 Testing among Underserved and Vulnerable Populations (U01 Clinical Trial Optional), RFA-OD-22-006, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 Clinical Trial Optional), RFA-DA-23-003, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional), RFA-NS-22-050, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes & Cells (U19 Clinical Trial Not Allowed), RFA-NS-22-018, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Human Pain-associated Genes & Cells Data Coordination and Integration Center (U24 Clinical Trial Not Allowed), RFA-NS-22-021, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Required), PAR-22-112, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Optional), PAR-22-113, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Advancing Integrated Models (AIM) of Care to Improve Maternal Health Outcomes among Women Who Experience Persistent Disparities (R01 Clinical Trial Required), RFA-NR-22-002, National Institutes of Health (NIH), National Institute of Nursing Research (NINR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed), RFA-DE-22-011, National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

Emergency Award HEAL Initiative: Optimizing Existing Evidence-Based Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional), RFA-MH-22-175, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

Emergency Award HEAL Initiative: Developing and Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional), RFA-MH-22-176, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed), RFA-TR-22-013, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required), RFA-NS-22-037, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 Clinical Trial Optional), RFA-MD-22-007, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH)

Emergency Awards: HEAL Initiative-Limited Competition: HEAL Initiative Resource Centers for the Pain Management Effectiveness Research Network (ERN) (U24 Clinical Trial Not Allowed), RFA-TR-22-012, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH), National Center for Advancing Translational Sciences (NCATS), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional), RFA-DA-22-038, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional), RFA-DA-22-037, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: National K12 Clinical Pain Career Development Program (K12 Clinical Trial Not Allowed), RFA-NS-22-045, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)

HEAL Initiative: Coordinating Center for National Pain Scientists Career Development (R24 Clinical Trial Not Allowed), RFA-NS-22-046, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Restoring Joint Health and Function to Reduce Pain Consortium (RE-JOIN) (UC2 Clinical Trial Not Allowed), RFA-AR-22-009, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed), RFA-NS-22-034, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

HEAL Initiative: HEAL Data2Action Modeling and Economic Resource Center (U24 Clinical Trial Optional), RFA-DA-049, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: HEAL Data2Action Research Adoption Support Center (U2C Clinical Trial Optional), RFA-DA-22-050, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional), RFA-DA-22-051, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Pilot & Feasibility Trials to Improve Prevention and Treatment Service Delivery for Polysubstance Use (R34 Clinical Trial Optional), RFA-DA-22-048, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional), RFA-DA-22-047, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional), RFA-DA-22-046, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Research Networks for the Study of Recovery Support Services for Persons Treated with Medications for Opioid Use Disorder (R24 Clinical Trial Optional), RFA-DA-22-043, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders: Coordination Center (R24 Clinical Trial Optional), RFA-DA-22-042, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

HEAL Initiative: Planning Grants for Efficacy or Effectiveness Trials of Recovery Support Services for Individuals Treated with Medications for Opioid Use Disorder (R34 Clinical Trial Optional), RFA-DA-22-034, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21- Clinical Trial Not Allowed), RFA-DA-22-045, National Institutes of Health, National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed), RFA-DA-22-044, National Institutes of Health, National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH)

Center for Rapid Surveillance of Tobacco (CRST) to Assess Changes in Use Behaviors, Product Marketing, and the Marketplace (U01 Clinical Trial Not Allowed), RFA-OD-22-002, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), National Cancer Institute (NCI)

Risk and Protective Factors of Family Health and Family Level Interventions (R01 - Clinical Trial Optional), PAR-21-358, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Nursing Research (NINR), National Cancer Institute (NCI)

Research Centers in Minority Institutions (RCMI) (U54 Clinical Trials Optional), RFA-MD-22-002, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)

NIH HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 Clinical Trials Optional), RFA-DA-22-036, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Mental Health (NIMH)

Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities (R01 Clinical Trial Optional), PAR-22-064, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Deafness and Other Communication Disorders (NIDCD)

Understanding Place-Based Health Inequalities in Mid-Life (R01 Clinical Trial Not Allowed), RFA-AG-23-004, National Institutes of Health (NIH)

HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required), RFA-AT-22-003, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS)

Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required), RFA-MH-22-150, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Home and Community-Based Physical Activity Interventions to Improve the Health of Wheelchair Users (R01 Clinical Trial Required), RFA-HD-22-017, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required), RFA-AT-22-005, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Advancing Translational Sciences (NCATS)

HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional), RFA-AT-22-004, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

Clinical Research Education and Career Development (CRECD) Program (R25-Independent Clinical Trial Not Allowed), PAR-21-347, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Nursing Research (NINR)

NIH Health Care Systems Research Collaboratory - Pragmatic and Implementation Trials of Embedded Interventions (UG3/UH3, Clinical Trials Optional), RFA-AT-22-001, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)

HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required), RFA-NS-22-002, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)

Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional), RFA-ES-21-007, National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS)

Pediatric Obesity Discovery Science Research to Improve Understanding of Risk and Causal Mechanisms for Obesity in Early Life (R01 Clinical Trial Optional), RFA-DK-21-025, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

HEAL initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression Without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development) (UG3/UH3 Clinical Trials Not Allowed), RFA-HL-22-013, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA)

Investigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Exploratory/Developmental Research Grant Award (R21 Clinical Trial Not Allowed), RFA-OD-21-007, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP), National Cancer Institute (NCI)

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional), PAS-21-270, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immunogenicity in Severe Hemophilia A: Hemophilia A Analytical Cohort Research Program (UG3/UH3 Clinical Trial Not Allowed), RFA-HL-22-004, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

High Priority HIV and Substance Use Research (R01 Clinical Trial Optional), RFA-DA-22-040, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R01 - Clinical Trial Optional), RFA-DA-22-028, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R21 - Clinical Trial Optional), RFA-DA-22-039, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional), PAR-22-027, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional), RFA-NS-22-016, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS)

Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional), RFA-DA-22-022, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional), PAR-21-303, National Institutes of Health (NIH)

Imaging - Science Track Award for Research Transition (I/START) (R03- Basic Experimental Studies with Humans Required), PAR-21-309, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Imaging - Science Track Award for Research Transition (I/START) (R03- Clinical Trial Optional), PAR-21-310, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Advancing Validated Drug Targets for Substance Use Disorders (R41/R42 - Clinical Trial Not Allowed), RFA-DA-22-018, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed), RFA-DA-22-033, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional), RFA-DA-23-001, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed), RFA-DA-22-032, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed), RFA-DA-22-031, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)

Exploratory Studies to Investigate the Mechanisms of Interrelationship between Sleep and Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans Required), RFA-DA-22-029, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional), PAR-21-275, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Cancer Institute (NCI)

Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R34 Clinical Trial Required), RFA-MH-21-241, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R01 Clinical Trial Required), RFA-MH-21-240, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Elucidating the Effects of ART on Neuronal Function in the Context of SUD and HIV (R01 - Clinical Trials Not Allowed), RFA-DA-22-003, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Large Scale Mapping and/or Molecular Profiling of Ensembles and/or Cell-Types Mediating Opioid Action in the Rodent Brain (R01 - Clinical Trial Not Allowed), RFA-DA-22-011, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Organoid Modeling of Neural Stimulants and HIV Comorbidity of Human Brain (R01- Clinical Trial Optional), RFA-DA-22-009, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional), RFA-DA-22-017, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NIDA Animal Genomics Program (U01 - Clinical Trial Not Allowed), PAR-21-244, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Exploratory Studies to Investigate the Mechanisms of Interrelationship Between Sleep and Substance Use Disorders (R61/R33 Clinical Trials Not Allowed), RFA-DA-22-016, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Assessing the Effects of Cannabinoids on HIV-Associated Persistent Inflammation (R01 Clinical Trial Optional), RFA-DA-22-012, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Basic Experimental Studies with Humans Required), RFA-DA-22-030, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Basic Experimental Studies with Humans Required), RFA-DA-22-024, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 Clinical Trial Not Allowed), RFA-DA-22-007, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mechanistic studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Clinical Trial Not Allowed), RFA-DA-22-005, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required), PAR-21-237, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional), PA-21-180, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required), PA-21-205, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional), RFA-DA-22-001, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required), RFA-MH-21-230, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

NIMHD Multiple Chronic Disease Disparities Research Coordinating Center (RCC) (U24 Clinical Trial Not Allowed), RFA-MD-21-008, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)

Centers for Multiple Chronic Diseases Associated with Health Disparities: Prevention, Treatment, and Management (P50 Clinical Trial Required), RFA-MD-21-007, National Institute on Minority Health and Health Disparities (NIMHD)

Emergency Award: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional), RFA-OD-21-009, National Institutes of Health (NIH)

Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations - RADx-UP Phase II (U01 Clinical Trial Optional), RFA-OD-21-008, National Institutes of Health (NIH)

Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed), RFA-DA-22-021, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R43/R44 - Clinical Trial Not Allowed), RFA-DA-22-019, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed), PAR-21-213, National Institutes of Health (NIH) National Institute on Aging (NIA), National Eye Institute (NEI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD)

Limited Competition Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed), RFA-DA-22-002, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional), PAR-21-208, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional), PAR-21-183, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional), RFA-MD-21-004, National Institutes of Health (NIH)

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required), PAR-21-132, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-21-002, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA)

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed), RFA-AA-21-003, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed), RFA-AA-21-002, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism. (NIAAA)

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed), RFA-AA-21-004, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed), RFA-DA-22-004, National Institutes of Health, National Institute on Drug Abuse (NIDA)

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed), PAR-21-062, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required), RFA-DA-21-030, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Mental Health; National Center for Complement

HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Coordination and Dissemination Center (R24 Clinical Trial Optional), RFA-DA-21-029, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Mental Health; National Center for Complement

HEAL Initiative: HEALthy Brain and Child Development Study (Collaborative U01- Clinical Trial Not Allowed), RFA-DA-21-020, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; National Institute of Child Health and Human Development; National Institute

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed), PAR-21-062, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases

Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional), PAS-21-031, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases

Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed), RFA-HG-22-010, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)

Multi-Omics for Health and Disease - 'Omics Production Centers (U01 Clinical Trial Not Allowed), RFA-HG-22-009, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)

Multi-Omics for Health and Disease - Disease Study Sites (U01 Clinical Trial Optional), RFA-HG-22-008, National Institutes of Health (NIH), National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional), PAR-21-092, National Institutes of Health; National Institute on Drug Abuse

Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with, RFA-OD-20-023, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases;

Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional), RFA-OD-20-022, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Aging; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Diso

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed), RFA-OD-20-021, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Nat

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed), RFA-OD-20-020, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Nat

Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed), RFA-OD-20-019, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of

Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed), RFA-OD-20-018, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; National Institute on Aging; National Institute of Dental and Craniofacial Research;

Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed), RFA-OD-20-017, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculosk

Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional), RFA-OD-20-016, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Disea

Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed), RFA-OD-20-015, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Drug Abuse; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Library of Medicine; This

Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed), RFA-OD-20-014, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Nationa

Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional), PAR-20-286, National Institutes of Health; National Institute of Mental Health

Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional), PAR-20-279, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

NIDA Core Center of Excellence Grant Program (P30 Clinical Trial Optional), PAR-20-267, National Institutes of Health; National Institute on Drug Abuse

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional), PAR-20-249, National Institutes of Health; National Institute on Drug Abuse

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional), PAR-20-237, National Institutes of Health; National Institute on Minority Health and Health Disparities; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health

Improving Smoking Cessation Interventions among People Living with HIV (R21 Clinical Trial Optional), RFA-CA-20-036, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse

Improving Smoking Cessation Interventions among People Living with HIV (R01 Clinical Trial Optional), RFA-CA-20-035, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse; National Institute on Minority Health and Health Disparities

Advancing Genomic Medicine Research (Clinical Trial Optional) (R21), RFA-HG-20-037, National Institutes of Health; National Human Genome Research Institute

Advancing Genomic Medicine Research (Clinical Trial Optional) (R01), RFA-HG-20-036, National Institutes of Health; National Human Genome Research Institute

Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional), RFA-OD-20-013, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Minority Health and Health Disparities; National Institute on Aging; National Eye Institute; National Heart, Lung, and Blood Institute; National Hu

NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional), PAR-20-221, National Institutes of Health; National Institute on Drug Abuse

Post-Acute Interventions for the Treatment of Anorexia Nervosa (R34 Clinical Trial Required), RFA-MH-20-500, National Institutes of Health; National Institute of Mental Health

NIDA Small Research Grant Program (R03 Clinical Trial Required), PA-20-146, National Institutes of Health; National Institute on Drug Abuse

Implementing the HIV Service Cascade for Justice-Involved Populations (U01 Clinical Trial Required), RFA-DA-20-028, National Institutes of Health; National Institute on Drug Abuse

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required), RFA-OD-20-011, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; U.S. Food and Drug Administration, Center for Tobacco Products

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required), RFA-OD-20-010, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed), RFA-OD-20-009, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed), RFA-OD-20-008, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional), PAR-20-092, National Institutes of Health; National Institute on Drug Abuse

Genomic Community Resources (U24 Clinical Trial Not Allowed), PAR-20-100, National Institutes of Health; National Human Genome Research Institute; National Cancer Institute

Safety and Feasibility Trials for Rapid-Acting Interventions for Severe Suicide Risk (R01 Clinical Trial Required), RFA-MH-20-345, National Institutes of Health; National Institute of Mental Health

Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R01 Clinical Trial Optional), RFA-MH-20-505, National Institutes of Health; National Institute of Mental Health

Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R34 Clinical Trial Required), RFA-MH-20-506, National Institutes of Health; National Institute of Mental Health

Enhancing Suicide Prevention in Emergency Care via Telehealth (R01 Clinical Trial Optional), RFA-MH-20-226, National Institutes of Health; National Institute of Mental Health

Early Psychosis Intervention Network (EPINET): Practice-Based Research to Improve Treatment Outcomes (R01 Clinical Trial Optional), RFA-MH-20-205, National Institutes of Health; National Institute of Mental Health

Dysregulation and Proximal Risk for Suicide (R01 Clinical Trial Optional), RFA-MH-20-327, National Institutes of Health; National Institute of Mental Health

Dysregulation and Proximal Risk for Suicide (R21 Clinical Trial Optional), RFA-MH-20-326, National Institutes of Health; National Institute of Mental Health

Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (Collaborative U01 Clinical Trial Not Allowed), PAR-20-027, National Institutes of Health; National Institute of Mental Health

Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (U01 Clinical Trial Not Allowed), PAR-20-026, National Institutes of Health; National Institute of Mental Health

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-19-028, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Environment

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional), PAR-19-368, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute

The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required), RFA-DA-20-024, National Institutes of Health; National Institute on Drug Abuse

NIDA Program Project Grant Applications (P01 Clinical Trial Optional), PAR-19-345, National Institutes of Health; National Institute on Drug Abuse

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional), PAR-19-327, National Institutes of Health; National Institute on Drug Abuse

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01-Clinical Trial Optional), PAR-19-318, National Institutes of Health; National Institute on Drug Abuse

Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed), RFA-DA-20-023, National Institutes of Health; National Institute on Drug Abuse

Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional), PAR-19-310, National Institutes of Health; National Institute on Drug Abuse

PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional), RFA-DA-20-013, National Institutes of Health; National Institute on Drug Abuse

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional), PAR-19-259, National Institutes of Health; National Institute on Drug Abuse

Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed), RFA-HL-20-014, National Institutes of Health; National Heart, Lung, and Blood Institute; National Center for Advanced of Translational Sciences

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis, Informatics and Resource Center (U24 Clinical Trial Not Allowed), RFA-DA-20-003, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Linked Research Project Sites (Collaborative U01 Clinical Trial Not Allowed), RFA-DA-20-002, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Coordinating Center (U24 Clinical Trial Not Allowed), RFA-DA-20-004, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required), PAR-19-236, National Institutes of Health; National Institute of Mental Health

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required), PAR-19-235, National Institutes of Health; National Institute of Mental Health

Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional), PAR-19-212, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), PAR-19-213, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Centers of Excellence in Genomic Science (RM1 Clinical Trials Optional), PAR-19-204, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-19-019, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Refinement and Testing of Interventions to Sustain ADHD Treatment Effects Across Settings and Developmental Transitions (R34 Clinical Trial Required), RFA-MH-20-100, National Institutes of Health; National Institute of Mental Health

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed), PAR-19-162, National Institutes of Health; National Institute on Drug Abuse; National Institute on Minority Health and Health Disparities; National Institute of Mental Health; National Cancer Institute; National Center for Complementary and Integrative Health; Nation

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed), PAR-19-163, National Institutes of Health; National Institute on Drug Abuse; National Institute of Neurological Disorders and Stroke; National Institute on Minority Health and Health Disparities; National Institute of Mental Health; National Cancer Institute; Eunice

Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders (UG1 Clinical Trial Required), RFA-DA-19-018, National Institutes of Health; National Institute on Drug Abuse

HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) (UG3/UH3 Clinical Trial Required), RFA-DA-19-035, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute of Child Health and Huma

HEAL Initiative: Effectiveness Trials to Optimize, Implement, Scale, and Sustain the Collaborative Care Model for Individuals with Opioid Use Disorders and Mental Health Conditions (U01 Clinical Trial Required), RFA-MH-19-525, National Institutes of Health; National Institute of Mental Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Nursing Research; National Institute on Minority H

HEAL Initiative: Coordinating Center to Support NIDA Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) Initiative (U24 Clinical Trial Not Allowed), RFA-DA-19-034, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute of Child Health and Huma

HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Clinical Research Centers (UG1 Clinical Trial Optional), RFA-DA-19-025, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Coordination and Translation Center (U2C Clinical Trial Optional), RFA-DA-19-024, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Methodology and Advanced Analytics Resource Center (U2C Clinical Trial Not Allowed), RFA-DA-19-023, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed), PA-19-043, National Institutes of Health; National Human Genome Research Institute

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional), PAR-19-064, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

HEALing Communities Study: Developing and Testing an Integrated Approach to Address the Opioid Crisis (Data Coordinating Center) (UM1 - Clinical Trials Not Allowed), RFA-DA-19-017, National Institutes of Health; Substance Abuse and Mental Health Services Administration; National Institute on Drug Abuse

HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional), PAS-18-915, National Institutes of Health; National Institute on Drug Abuse

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional), PA-18-916, National Institutes of Health; National Institute on Drug Abuse

Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional), PAR-18-918, National Institutes of Health; National Institute on Drug Abuse

Responding to Opioid Use Disorders (OUD) in Tribal Communities in the Context of SAMHSA and CDC Funding (R61/R33 - Clinical Trials Optional), RFA-DA-19-013, National Institutes of Health; National Institute on Drug Abuse; Office of Behavioral and Social Sciences Research; Tribal Health Research Office

HEALing Communities Study: Developing and Testing an Integrated Approach to Address the Opioid Crisis (Research Sites) (UM1 - Clinical Trial Required), RFA-DA-19-016, National Institutes of Health; Substance Abuse and Mental Health Services Administration; National Institute on Drug Abuse

The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Optional), RFA-DA-19-008, National Institutes of Health; National Institute on Drug Abuse

Dysregulation and Proximal Risk for Suicide FOA (R01 Clinical Trial Optional), RFA-MH-19-211, National Institutes of Health; National Institute of Mental Health

Dysregulation and Proximal Risk for Suicide (R21 Clinical Trial Optional), RFA-MH-19-210, National Institutes of Health; National Institute of Mental Health

Improving Smoking Cessation Interventions among People Living with HIV (R21 Clinical Trial Optional), RFA-CA-18-028, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse

Improving Smoking Cessation Interventions among People Living with HIV (R01 Clinical Trial Optional), RFA-CA-18-027, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse; National Institute on Minority Health and Health Disparities

Early Psychosis Intervention Network (EPINET): Data Coordinating Center (U24 Clinical Trial Not Allowed), RFA-MH-19-151, National Institutes of Health; National Institute of Mental Health

Early Psychosis Intervention Network (EPINET): Practice-Based Research to Improve Treatment Outcomes (R01 Clinical Trial Optional), RFA-MH-19-150, National Institutes of Health; National Institute of Mental Health

Novel Approaches for Relating Genetic Variation to Function and Disease (R21 Clinical Trial Not Allowed), PA-18-867, National Institutes of Health; National Human Genome Research Institute

Novel Approaches for Relating Genetic Variation to Function and Disease (R01 Clinical Trial Not Allowed), PA-18-868, National Institutes of Health; National Human Genome Research Institute

Rare Genetic Syndromes as a Window into the Genetic Architecture of Mental Disorders (Collaborative U01 Clinical Trial Not Allowed), RFA-MH-19-201, National Institutes of Health; National Institute of Mental Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development

Rare Genetic Syndromes as a Window into the Genetic Architecture of Mental Disorders (U01 Clinical Trial Not Allowed), RFA-MH-19-200, National Institutes of Health; National Institute of Mental Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development

Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed), PAR-18-789, National Institutes of Health; National Institute on Drug Abuse

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed), RFA-OD-18-005, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; National Institute of Environmental Health Sciences

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required), RFA-OD-18-006, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required), RFA-OD-18-008, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed), RFA-OD-18-007, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; National Institute of Environmental Health Sciences

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 - Clinical Trial Optional), PA-18-780, National Institutes of Health; National Institute on Drug Abuse

International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional), PA-18-773, National Institutes of Health; National Institute on Drug Abuse

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional), PA-18-775, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional), PAR-18-746, National Institutes of Health; National Institute on Drug Abuse

Investigator-Initiated Genomic Medicine Research (R01 Clinical Trial Optional), PAR-18-735, National Institutes of Health; National Human Genome Research Institute

Investigator-Initiated Genomic Medicine Research (R21 Clinical Trial Optional), PAR-18-736, National Institutes of Health; National Human Genome Research Institute

Coordinating Center to Support NIDA Rural Opioid HIV and Comorbidity Initiative (U24 - Clinical Trial Not Allowed), RFA-DA-19-004, National Institutes of Health; National Institute on Drug Abuse

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01, Clinical Trial Optional), RFA-DA-18-022, National Institutes of Health; National Institute on Drug Abuse

Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment (R61/R33 Clinical Trial Required), RFA-DA-19-005, National Institutes of Health; National Institute on Drug Abuse

NIDA Small Research Grant Program (R03 Clinical Trial Required), PA-18-634, National Institutes of Health; National Institute on Drug Abuse

NIDA Small Research Grant Program (R03 Clinical Trial Required), PA-18-626, National Institutes of Health; National Institute on Drug Abuse

NIDA Academic Research Enhancement Award (R15, Clinical Trials Required), PA-18-627, National Institutes of Health; National Institute on Drug Abuse

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01, Clinical Trial Optional), PA-18-569, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

International Research Collaboration on Drug Abuse and Addiction Research (R01, Clinical Trial Optional), PA-18-568, National Institutes of Health; National Institute on Drug Abuse

Improving Implementation of Seek, Test, Treat and Retain Strategies among People Who Inject Drugs in Low to Middle Income Countries (R01-Clinical Trial Required), RFA-DA-18-017, National Institutes of Health; National Institute on Drug Abuse

Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (R01- Clinical Trial Not Allowed), RFA-DA-18-023, National Institutes of Health; National Institute on Drug Abuse

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03 Clinical Trial Optional), PAR-18-527, National Institutes of Health; National Institute on Drug Abuse

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 ), PAR-18-510, National Institutes of Health; National Institute on Drug Abuse

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21 Clinical Trial Optional ), PAR-18-509, National Institutes of Health; National Institute on Drug Abuse

Device-Based Treatments for Substance Use Disorders (UG3/UH3) (Clinical Trial Optional), PAR-18-494, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional), RFA-DA-19-002, National Institutes of Health; National Institute on Drug Abuse

Pilot Effectiveness Trials for Post-Acute Interventions and Serivces to Optimize Longer-Term Outcomes (R34-Clinical Trials Required), PAR-18-431, National Institutes of Health; National Institute of Mental Health

Effectiveness Trials for Post-Acute Interventions and Services and Services to Optimize Longer-Term Outcomes (R01-Clinical Trials Required), PAR-18-430, National Institutes of Health; National Institute of Mental Health

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3, Clinical Trial Optional), RFA-DA-18-020, National Institutes of Health; National Institute on Drug Abuse

NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional), RFA-DA-18-019, National Institutes of Health; National Institute on Drug Abuse

NIDA Core Center of Excellence Grant Program (P30 Clinical Trial Optional), PAR-18-225, National Institutes of Health; National Institute on Drug Abuse

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional), PAR-18-224, National Institutes of Health; National Institute on Drug Abuse

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional), PAR-18-226, National Institutes of Health; National Institute on Drug Abuse

NIDA Program Project Grant Applications (P01, Clinical Trial Optional), PAR-18-425, National Institutes of Health; National Institute on Drug Abuse

Fast-Track Development of Medications to Treat Cannabis Use Disorders (UG3/UH3 Clinical Trial Optional), PAR-18-221, National Institutes of Health; National Institute on Drug Abuse

Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required), PAR-18-233, National Institutes of Health; National Institute of Mental Health

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required), PAR-18-232, National Institutes of Health; National Institute of Mental Health

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional), PAR-18-219, National Institutes of Health; National Institute on Drug Abuse

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01 Clinical Trial Optional), PAR-18-218, National Institutes of Health; National Institute on Drug Abuse

Ancillary Studies to Identify Behavioral and/or Psychological Phenotypes Contributing to Obesity (R01 Clinical Trial Optional), PAR-18-105, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; Office of Behavioral and Social Sciences Research

Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional), RFA-OD-18-001, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-18-002, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Tobacco Regulatory Science (R21 Clinical Trial Optional), RFA-OD-18-003, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional), PAR-18-082, National Institutes of Health; National Institute on Drug Abuse

Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional), PAR-18-081, National Institutes of Health; National Institute on Drug Abuse; National Institute of Biomedical Imaging and Bioengineering

Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33), RFA-AT-18-002, National Institutes of Health; National Center for Complementary and Integrative Health

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional), PA-18-072, National Institutes of Health; National Institute on Drug Abuse

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 Clinical Trial Optional), PA-18-071, National Institutes of Health; National Institute on Drug Abuse

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21 Clinical Trial Optional), PA-18-070, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03 Clinical Trial Optional), PA-18-069, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34 Clinical Trial Optional), PA-18-068, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional), PA-18-067, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

International Research Collaboration on Drug Abuse and Addiction Research (R21 Clinical Trial Optional), PA-18-066, National Institutes of Health; National Institute on Drug Abuse

International Research Collaboration on Drug Abuse and Addiction Research (R03 Clinical Trial Optional), PA-18-065, National Institutes of Health; National Institute on Drug Abuse

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01- Clinical Trial Required), RFA-MH-18-707, National Institutes of Health; National Institute of Mental Health

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required), RFA-MH-18-706, National Institutes of Health; National Institute of Mental Health

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33- Clinical Trial Required), RFA-MH-18-705, National Institutes of Health; National Institute of Mental Health

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33- Clinical Trial Required), RFA-MH-18-704, National Institutes of Health; National Institute of Mental Health

Early Stage Testing of Pharmacologic or Device -based Interventions for the Treatment of Mental Health Disorders (R33- Clinical Trial Required), RFA-MH-18-703, National Institutes of Health; National Institute of Mental Health

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33-Clinical Trial Required), RFA-MH-18-702, National Institutes of Health; National Institute of Mental Health

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01- Clinical Trial Required), RFA-MH-18-701, National Institutes of Health; National Institute of Mental Health

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01-Clinical Trial Required), RFA-MH-18-700, National Institutes of Health; National Institute of Mental Health

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional), PAR-18-064, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute

Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional), PA-18-078, National Institutes of Health; National Institute on Drug Abuse

Neuroscience Research on Drug Abuse (R01 Clinical Trial Optional), PA-18-060, National Institutes of Health; National Institute on Drug Abuse

Prescription Drug Abuse (R21 Clinical Trial Optional), PA-18-076, National Institutes of Health; National Institute on Drug Abuse

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21 Clinical Trial Optional), PA-18-075, National Institutes of Health; National Institute on Drug Abuse

Behavioral and Integrative Treatment Development Program (R03 Clinical Trial Optional), PA-18-074, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), PA-18-073, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Prescription Drug Abuse (R01 Clinical Trial Optional), PA-18-058, National Institutes of Health; National Institute on Drug Abuse

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01 Clinical Trial Optional), PA-18-056, National Institutes of Health; National Institute on Drug Abuse

Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional), PA-18-055, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional), PAR-18-062, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism

The Application of Big Data Analytics to Drug Abuse Research (R01 Clinical Trial Optional), PA-18-057, National Institutes of Health; National Institute on Drug Abuse

Pharmacogenomics of Anti-retroviral Therapy in People Who Inject Drugs (R01), RFA-DA-18-014, National Institutes of Health; National Institute on Drug Abuse

Tobacco Regulatory Science Small Grant Program for New Investigators (R03), RFA-OD-17-012, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Tobacco Regulatory Science (R21), RFA-OD-17-014, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Tobacco Regulatory Science (R01), RFA-OD-17-013, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

The NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL) (U24), RFA-HG-17-011, National Institutes of Health; National Human Genome Research Institute

Limited Competition Cohort Studies of HIV/AIDS and Substance Abuse (U01), RFA-DA-18-011, National Institutes of Health; National Institute on Drug Abuse

HIV/HCV Co-Infections in Substance Abusers (R01), PAS-17-311, National Institutes of Health; National Institute on Drug Abuse

Addressing Suicide Research Gaps: Understanding Mortality Outcomes (R01), RFA-MH-18-410, National Institutes of Health; National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute on Drug Abuse; National Institue on Minority Health and Health Disparities

Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33), RFA-AT-18-001, National Institutes of Health; National Center for Complementary and Integrative Health

Tobacco Regulatory Science (R21), RFA-OD-17-009, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Tobacco Regulatory Science Small Grant Program for New Investigators (R03), RFA-OD-17-008, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Tobacco Regulatory Science (R01), RFA-OD-17-007, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

Genomic Community Resources (U24), PAR-17-273, National Institutes of Health; National Human Genome Research Institute; National Cancer Institute

Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01), PAR-17-272, National Institutes of Health; National Institute of Mental Health

Pilot Effectivness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34), PAR-17-271, National Institutes of Health; National Institute of Mental Health

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (Collaborative R01), PAR-17-252, National Institutes of Health; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (R01), PAR-17-253, National Institutes of Health; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism

Expanding Medication Assisted Treatment for Opioid Use Disorders in the Context of the SAMHSA Opioid STR Grants (R21/R33), RFA-DA-18-005, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicles and Substance Use Disorders (R21), PAR-17-242, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicles and Substance Use Disorders (R01), PAR-17-250, National Institutes of Health; National Institute on Drug Abuse

Center for Coordination of Analytics, Science, Enhancement , and Logistics (CASEL) in Tobacco Regulatory Science (U54), RFA-OD-17-002, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Institute on Drug Abuse; U.S. Food and Drug Administration, Center for Tobacco P

Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54), RFA-OD-17-003, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3), RFA-DA-18-003, National Institutes of Health; National Institute on Drug Abuse

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (Collaborative U01), PAR-17-176, National Institutes of Health; National Institute of Mental Health

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (U01), PAR-17-179, National Institutes of Health; National Institute of Mental Health

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R21), PA-17-157, National Institutes of Health; National Institute on Drug Abuse

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R01), PA-17-155, National Institutes of Health; National Institute on Drug Abuse

Basic Mechanisms of Brain Development Mediating Substance Use and Dependence (R01), PA-17-119, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01), PA-17-120, National Institutes of Health; National Institute on Drug Abuse

Neuroscience Research on Drug Abuse (R21), PA-17-112, National Institutes of Health; National Institute on Drug Abuse

Neuroscience Research on Drug Abuse (R01), PA-17-111, National Institutes of Health; National Institute on Drug Abuse

NIDA Core Center of Excellence Grant Program (P30), PAR-17-121, National Institutes of Health; National Institute on Drug Abuse

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01), RFA-MH-17-614, National Institutes of Health; National Institute of Mental Health

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34), RFA-MH-17-612, National Institutes of Health; National Institute of Mental Health

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01), RFA-MH-17-610, National Institutes of Health; National Institute of Mental Health

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33), RFA-MH-17-602, National Institutes of Health; National Institute of Mental Health

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01), RFA-MH-17-608, National Institutes of Health; National Institute of Mental Health

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33), RFA-MH-17-604, National Institutes of Health; National Institute of Mental Health

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33), RFA-MH-17-606, National Institutes of Health; National Institute of Mental Health

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33), RFA-MH-17-600, National Institutes of Health; National Institute of Mental Health

NIH-DoD-VA Pain Management Collaboratory - Pragmatic Clinical Trials Demonstration Projects (UG3/UH3), RFA-AT-17-001, National Institutes of Health; Department of Defense; Department of Veterans Affairs; National Center for Complementary and Integrative Health; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health a

Hepatitis C Virus (HCV) Advanced Molecular Detection in Support of Systems for Prevention, Treatment and Control of HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States (U24), RFA-DA-17-023, National Institutes of Health; Centers for Disease Control and Prevention; National Institute on Drug Abuse; National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention

HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control (UG3/UH3), RFA-DA-17-014, National Institutes of Health; Centers for Disease Control and Prevention; Substance Abuse and Mental Health Services Administration; Appalachian Regional Commission; National Institute on Drug Abuse; National Center for HIV/AIDS, Viral Hepatitis, STD and

Drug Abuse Dissertation Research (R36), PA-16-443, National Institutes of Health; National Institute on Drug Abuse

Centers of Excellence in Genomic Science (CEGS) (RM1), PAR-16-436, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01), PAR-16-430, National Institutes of Health; National Institute on Drug Abuse

Grand Opportunity in Medications Development for Substance-Use Disorders (U01), PAR-16-431, National Institutes of Health; National Institute on Drug Abuse

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24), RFA-DA-17-019, National Institutes of Health; National Institute on Drug Abuse

NIDA Program Project Grant Applications (P01), PAR-16-393, National Institutes of Health; National Institute on Drug Abuse

Chemistry Science Track Award for Rapid Transition (C/START) (R03), PAR-16-383, National Institutes of Health; National Institute on Drug Abuse

Chemical Discovery (CHEM) Award (R21/R33), PAR-16-384, National Institutes of Health; National Institute on Drug Abuse

Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01), RFA-DA-17-013, National Institutes of Health; National Institute on Drug Abuse

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1), PAR-16-357, National Institutes of Health; National Institute on Drug Abuse

Ancillary Studies to Identify Behavioral and/or Psychological Phenotypes Contributing to Obesity (R01), PAR-16-304, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; Office of Behavioral and Social Sciences Research

Reducing the Duration of Untreated Psychosis in the United States (R01), PAR-16-265, National Institutes of Health; National Institute of Mental Health

Reducing the Duration of Untreated Psychosis in the United States (R34), PAR-16-264, National Institutes of Health; National Institute of Mental Health

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01), PAR-16-234, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism

Prescription Drug Abuse (R21), PA-16-232, National Institutes of Health; National Institute on Drug Abuse

Prescription Drug Abuse (R01), PA-16-233, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicle Tools, Technologies, and Products for Neuroscience Research (R41/R42), RFA-DA-17-008, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicle Tools, Technologies, and Products for Neuroscience Research (R43/R44), RFA-DA-17-009, National Institutes of Health; National Institute on Drug Abuse

Role of Astrocytes and Astrocytic Networks in Drug Abuse (R21), PA-16-145, National Institutes of Health; National Institute on Drug Abuse

Role of Astrocytes and Astrocytic Networks in Drug Abuse (R01), PA-16-144, National Institutes of Health; National Institute on Drug Abuse

The Application of Big Data Analytics to Drug Abuse Research (R01), PA-16-119, National Institutes of Health; National Institute on Drug Abuse

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3), RFA-DA-17-015, National Institutes of Health; National Institute on Drug Abuse

Services Planning Research in the Appalachian Region to Address Adverse Health Consequences Associated with Increased Opioid Injection Drug Use (R03), RFA-DA-16-015, National Institutes of Health; Appalachian Regional Commission; National Institute on Drug Abuse

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21), PA-16-075, National Institutes of Health; National Institute on Drug Abuse

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01), PA-16-076, National Institutes of Health; National Institute on Drug Abuse

Behavioral and Integrative Treatment Development Program (R03), PA-16-074, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Behavioral and Integrative Treatment Development Program (R01), PA-16-072, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Behavioral and Integrative Treatment Development Program (R34), PA-16-073, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Behavioral Science Track Award for Rapid Transition (B/Start)(R03), PAR-16-071, National Institutes of Health; National Institute on Drug Abuse

Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01), RFA-DA-16-012, National Institutes of Health; National Institute on Drug Abuse

Systems Biology Approaches in HIV/AIDS and Substance Use (R01), RFA-DA-16-013, National Institutes of Health; National Institute on Drug Abuse

Mechanism for Time-Sensitive Drug Abuse Research (R21), PAR-16-055, National Institutes of Health; National Institute on Drug Abuse

Seek, Test, Treat and Retain For Youth and Young Adults Living with or at High Risk for Acquiring HIV (R01), RFA-DA-16-010, National Institutes of Health; National Institute on Drug Abuse

Effects of Drugs of Abuse on Latent HIV Reservoirs in the CNS (R01), RFA-DA-16-014, National Institutes of Health; National Institute on Drug Abuse

Integration of Infectious Diseases and Substance Abuse Intervention Services for Individuals Living with HIV (R01), RFA-DA-16-011, National Institutes of Health; National Institute on Drug Abuse

Environmental Influences on Child Health Outcomes: Patient Reported Outcomes Research Resource Center Core (ECHO PRO Core) (U24), RFA-OD-16-003, National Institutes of Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Nationa

Environmental Influences on Child Health Outcomes (ECHO) Pediatric Cohorts (UG3/UH3), RFA-OD-16-004, National Institutes of Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Nationa

NIDA Research Center of Excellence Grant Program (P50), PAR-16-009, National Institutes of Health; National Institute on Drug Abuse

Major Opportunities for Research in Epidemiology of Alzheimer's Disease and Cognitive Resilience (R01), PAR-15-356, National Institutes of Health; National Institute on Aging

AIDS-Science Track Award for Research Transition (R03), PA-15-290, National Institutes of Health; National Institute on Drug Abuse

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3), RFA-DA-16-008, National Institutes of Health; National Institute on Drug Abuse

Imaging - Science Track Award for Research Transition (I/START) (R03), PAR-15-326, National Institutes of Health; National Institute on Drug Abuse; National Institute of Biomedical Imaging and Bioengineering

Tools for Monitoring and Manipulating Modified RNAs in the Nervous System (R43/R44), RFA-DA-16-005, National Institutes of Health; National Institute on Drug Abuse

Tools for Monitoring and Manipulating Modified RNAs in the Nervous System (R41/R42), RFA-DA-16-006, National Institutes of Health; National Institute on Drug Abuse

Data Coordinating Center for Sickle Cell Disease Implementation Consortium (SCDIC): Using Implementation Science to Optimize Care of Adolescents and Adults with Sickle Cell Disease (U24), RFA-HL-16-011, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Minority Health and Health Disparities

Extracellular Vesicles and Substance Abuse (R21), PAR-15-284, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicles and Substance Abuse (R01), PAR-15-283, National Institutes of Health; National Institute on Drug Abuse

Longitudinal Assessment of Post -traumatic Syndromes (U01), RFA-MH-16-500, National Institutes of Health; National Institute of Mental Health

Tools and Services for Designing Methodologically Rigorous Animal Studies (R41/R42), RFA-DA-16-002, National Institutes of Health; National Institute on Drug Abuse

Tools and Services for Designing Methodologically Rigorous Animal Studies (R43/R44), RFA-DA-16-003, National Institutes of Health; National Institute on Drug Abuse

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34), PA-15-268, National Institutes of Health; National Institute on Drug Abuse; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health

Harnessing Genome Editing Technologies to Functionally Validate Genetic Variants in Substance Use Disorders (R21/R33), RFA-DA-16-004, National Institutes of Health; National Institute on Drug Abuse

Fast-Track Development of Medications to Treat Cannabis Use Disorders (UG3/UH3), PAR-15-267, National Institutes of Health; National Institute on Drug Abuse

Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R61/R33), RFA-MH-16-406, National Institutes of Health; National Institute of Mental Health

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03), PA-15-252, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34), PA-15-250, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01), PA-15-251, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34), PA-15-250, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21), PA-15-253, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34), PA-15-177, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Clinical Trials to Test the Effectiveness of Treatment, Preventive and Services Interventions (Collaborative R01), RFA-MH-16-415, National Institutes of Health; National Institute of Mental Health

Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R33), RFA-MH-16-400, National Institutes of Health; National Institute of Mental Health

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01), RFA-MH-16-420, National Institutes of Health; National Institute of Mental Health

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01), RFA-MH-16-425, National Institutes of Health; National Institute of Mental Health

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34), RFA-MH-16-410, National Institutes of Health; National Institute of Mental Health

International Research Collaboration on Drug Abuse and Addiction Research (R21), PA-15-143, National Institutes of Health; National Institute on Drug Abuse

International Research Collaboration on Drug Abuse and Addiction Research (R01), PA-15-142, National Institutes of Health; National Institute on Drug Abuse

International Research Collaboration on Drug Abuse and Addiction Research (R03), PA-15-141, National Institutes of Health; National Institute on Drug Abuse

Identification of Genetic and Genomic Variants by Next-Gen in Sequencing Non-human Animal Models (U01), PAR-15-120, National Institutes of Health; National Institute on Drug Abuse

NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12), PAR-15-119, National Institutes of Health; National Institute on Drug Abuse

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01), RFA-DA-16-001, National Institutes of Health; National Institute on Drug Abuse

Gene-Environment Interplay in Substance Use Disorders (R21), PA-15-112, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Gene-Environment Interplay in Substance Use Disorders (R03), PA-15-111, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Gene-Environment Interplay in Substance Use Disorders (R01), PA-15-110, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis and Informatics Center (U24), RFA-DA-15-016, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Adolescent Brain Cognitive Development (ABCD) Study - Research Project Sites (U01), RFA-DA-15-015, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Adolescent Brain Cognitive Development (ABCD) Study - Coordinating Center (U24), RFA-DA-15-014, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Reductions in Illicit Drug Use and Functional Outcomes (R21/R33), PA-15-099, National Institutes of Health; National Institute on Drug Abuse

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3), RFA-DA-15-017, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Prevention Intervention Research (R21), PA-15-080, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Prevention Intervention Research (R03), PA-15-081, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Prevention Intervention Research (R01), PA-15-082, National Institutes of Health; National Institute on Drug Abuse

Identification of Genetic and Genomic Variants by Next-Gen in Sequencing Non-human Animal Models (U01), PAR-15-120, National Institutes of Health; National Institute on Drug Abuse

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01), RFA-DA-16-001, National Institutes of Health; National Institute on Drug Abuse

Gene-Environment Interplay in Substance Use Disorders (R21), PA-15-112, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Gene-Environment Interplay in Substance Use Disorders (R03), PA-15-111, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis and Informatics Center (U24), RFA-DA-15-016, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H

Reductions in Illicit Drug Use and Functional Outcomes (R21/R33), PA-15-099, National Institutes of Health; National Institute on Drug Abuse

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3), RFA-DA-15-017, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Prevention Intervention Research (R01), PA-15-082, National Institutes of Health; National Institute on Drug Abuse

Children's Health Exposure Analysis Resource (CHEAR): Coordinating Center (U24), RFA-ES-15-011, National Institutes of Health; National Institute of Environmental Health Sciences

Epidemiology of Drug Abuse (R21), PA-15-001, National Institutes of Health; National Institute on Drug Abuse

Epidemiology of Drug Abuse (R03), PA-15-002, National Institutes of Health; National Institute on Drug Abuse

Epidemiology of Drug Abuse (R01), PA-15-003, National Institutes of Health; National Institute on Drug Abuse

Enhancing Cross-National Research within the Health and Retirement Study Family of Studies (R01), RFA-AG-15-015, National Institutes of Health; National Institute on Aging

Interventions for Youth who Misuse/Abuse Prescription Stimulant Medications in High School and/or College-Attending Youth (U01), RFA-DA-15-010, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicles in HIV/AIDS and Substance Abuse (R21), RFA-DA-15-012, National Institutes of Health; National Institute on Drug Abuse

Extracellular Vesicles in HIV/AIDS and Substance Abuse (R01), RFA-DA-15-011, National Institutes of Health; National Institute on Drug Abuse

The National Drug Abuse Treatment Clinical Trials Network (UG1), RFA-DA-15-008, National Institutes of Health; National Institute on Drug Abuse

Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R33), PAR-14-231, National Institutes of Health; National Institute on Drug Abuse; National Institute of Mental Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism

Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R21/R33), PAR-14-230, National Institutes of Health; National Institute on Drug Abuse; National Institute of Mental Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism

Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01), PAR-14-225, National Institutes of Health; National Institute on Drug Abuse; National Center for Complementary and Integrative Health; National Cancer Institute

Long-Term Retention in Care for U.S. Substance Using Populations (R01), PA-14-224, National Institutes of Health; National Institute on Drug Abuse

Long-Term Retention in Care for U.S. Substance Using Populations (R21), PA-14-223, National Institutes of Health; National Institute on Drug Abuse

Long-Term Retention in Care for U.S. Substance Using Populations (R34), PA-14-222, National Institutes of Health; National Institute on Drug Abuse

Centers of Excellence in Genomic Science (CEGS) (RM1), PAR-14-195, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health

Epidemiology and Prevention in Alcohol Research (R01), PA-14-190, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism

Epidemiology and Prevention in Alcohol Research (R03), PA-14-189, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism

Epidemiology and Prevention in Alcohol Research (R21), PA-14-188, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism

Genomic Resource Grants for Community Resource Projects (U41), PAR-14-191, National Institutes of Health; National Cancer Institute; National Human Genome Research Institute

NIDA Core Center of Excellence Grant Program (P30), PAR-14-186, National Institutes of Health; National Institute on Drug Abuse

Effects of Cannabis Use and Cannabinoids on the Developing Brain (R01), PA-14-163, National Institutes of Health; National Institute on Drug Abuse

Effects of Cannabis Use and Cannabinoids on the Developing Brain (R21), PA-14-162, National Institutes of Health; National Institute on Drug Abuse

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01), PA-14-137, National Institutes of Health; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney Diseases

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21), PA-14-136, National Institutes of Health; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney Diseases

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34), PA-14-135, National Institutes of Health; National Institute on Drug Abuse

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01), PAR-14-106, National Institutes of Health; National Institute on Drug Abuse

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21), PAR-14-105, National Institutes of Health; National ?Institute on Drug Abuse

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03), PAR-14-104, National Institutes of Health; National Institute on Drug Abuse

NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1), RFA-DA-15-004, National Institutes of Health; National Institute on Drug Abuse

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01), RFA-DA-15-005, National Institutes of Health; National Institute on Drug Abuse

Neuroimmune Signaling in Substance Use Disorders (R01), PA-14-084, National Institutes of Health; National Institute on Drug Abuse

Neuroimmune Signaling and Function in Substance Use Disorders (R21), PA-14-083, National Institutes of Health; National Institute on Drug Abuse

Medications Development Centers of Excellence Cooperative Program (U54), RFA-DA-15-003, National Institutes of Health; National Institute on Drug Abuse

Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R01), PA-14-061, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R21), PA-14-062, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R03), PA-14-063, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R21), PA-14-036, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03), PA-14-037, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R01), PA-14-038, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Basic Mechanisms of Brain Development for Substance Use and Dependence (R01), PA-14-026, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01), PA-14-025, National Institutes of Health; National Institute on Drug Abuse

Public Health Impact of the Changing Policy/Legal Environment for Marijuana (R01), PAS-14-020, National Institutes of Health; National Institute on Drug Abuse

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Abuse (R21), PA-14-013, National Institutes of Health; National Institute on Drug Abuse

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Abuse (R01), PA-14-014, National Institutes of Health; National Institute on Drug Abuse

Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM) (R21/R33), PAR-13-350, National Institutes of Health; National Institute on Drug Abuse

Neuroscience Research on Drug Abuse (R03), PA-13-336, National Institutes of Health; National Institute on Drug Abuse

Neuroscience Research on Drug Abuse (R21), PA-13-337, National Institutes of Health; National Institute on Drug Abuse

Neuroscience Research on Drug Abuse (R01), PA-13-338, National Institutes of Health; National Institute on Drug Abuse

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01), PAR-13-334, National Institutes of Health; National Institute on Drug Abuse

Administrative Supplements to Promote Collaborative Research on Addiction at NIH (CRAN): Comorbidity-Related Research (Admin Supp), PA-13-275, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism

Grand Opportunity in Medications Development for Substance-Use Disorders (U01), PAR-13-270, National Institutes of Health; National Institute on Drug Abuse

Seek, Test, Treat, and Retain Data Harmonization Coordinating Center (U01), RFA-DA-14-007, National Institutes of Health; National Institute on Drug Abuse

FY14 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1), RFA-DA-14-008, National Institutes of Health; National Institute on Drug Abuse

NIDA Research Center of Excellence Grant Program (P50), PAR-13-222, National Institutes of Health; National Institute on Drug Abuse

Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R01), RFA-DA-14-005, National Institutes of Health; National Institute on Drug Abuse

Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R21), RFA-DA-14-006, National Institutes of Health; National Institute on Drug Abuse

Medications Development Centers of Excellence Cooperative Program (U54), RFA-DA-14-004, National Institutes of Health; National Institute on Drug Abuse

Centers of Excellence in Genomic Science (CEGS) (P50), PAR-13-198, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health

Drug Abuse Dissertation Research (R36), PAR-13-182, National Institutes of Health; National Institute on Drug Abuse

Revision Applications to Promote Collaborative Research on Addiction at NIH (CRAN): Comorbidity-Related Research (R01), RFA-DA-14-014, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism

NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12), PAR-13-163, National Institutes of Health; National Institute on Drug Abuse

Prevention and Health Promotion Interventions to Prevent Alcohol and Other Drug Abuse and Associated Physical and Psychological Health Problems in U.S. Military Personnel, Veterans and their Families (R01), RFA-DA-13-012, National Institutes of Health; The Department of Defense; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of the Assistant Secretary of Defense for Health Affairs

Prevention and Health Promotion Interventions to Prevent Alcohol and Other Drug Abuse and Associated Physical and Psychological Health Problems in U.S. Military Personnel, Veterans and their Families (R34), RFA-DA-13-013, National Institutes of Health; The Department of Defense; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Center for Complementary and Alternative Medicine; Office of the Assistant Secretary of Defense for He

Behavioral & Integrative Treatment Development Program (R01), PA-13-077, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Center for Complementary and Integrative Health

Behavioral & Integrative Treatment Development Program (R34), PA-13-078, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Behavioral & Integrative Treatment Development Program (R03), PA-13-079, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01), PAR-13-080, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute

Prescription Drug Abuse (R01), PA-13-015, National Institutes of Health; National Institute on Drug Abuse

Prescription Drug Abuse(R21), PA-13-016, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Aspects of HIV/AIDS (R01), PA-12-293, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Aspects of HIV/AIDS (R03), PA-12-294, National Institutes of Health; National Institute on Drug Abuse

Drug Abuse Aspects of HIV/AIDS (R21), PA-12-295, National Institutes of Health; National Institute on Drug Abuse

HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21), PA-12-280, National Institutes of Health; National Institute on Drug Abuse

HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R01), PA-12-281, National Institutes of Health; National Institute on Drug Abuse

Human Heredity and Health in Africa (H3Africa): Collaborative Centers (U54), RFA-RM-12-006, National Institutes of Health; This Funding Opportunity Announcement; Division of Program Coordination, Planning and Strategic Initiatives; Office of Strategic Coordination; National Human Genome Research Institute; Eunice Kennedy Shriver National Institu

Human Heredity and Health in Africa (H3Africa): H3Africa Research Grants (U01), RFA-RM-12-007, National Institutes of Health; This Funding Opportunity Announcement; Division of Program Coordination, Planning and Strategic Initiatives; Office of Strategic Coordination; National Human Genome Research Institute; Eunice Kennedy Shriver National Institu

Behavioral Science Track Award for Rapid Transition (B/START) (R03), PAR-12-251, National Institutes of Health; National Institute on Drug Abuse

Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21), PAR-12-238, National Institutes of Health; National Institute on Drug Abuse

Human Heredity and Health in Africa (H3Africa): H3Africa Research Grants (U01), PAR-12-239, National Institutes of Health; This Funding Opportunity Announcement; Division of Program Coordination, Planning and Strategic Initiatives; Office of Strategic Coordination; National Human Genome Research Institute; Eunice Kennedy Shriver National Institu

Cohort Studies of HIV/AIDS and Substance Use (U01), PAR-12-222, National Institutes of Health; National Institute on Drug Abuse

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34), PA-12-231, National Institutes of Health; National Institute on Drug Abuse

Research Education Grants for Statistical and Computational Training in the Genetics of Addiction (R25), PAR-12-199, National Institutes of Health; National Institute on Drug Abuse

Small Grants for Behavioral Research in Cancer Control (R03), PAR-12-035, National Institutes of Health; National Cancer Institute

Gene-Environment Interplay in Substance Use Disorders (R21), PA-11-236, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Gene-Environment Interplay in Substance Use Disorders (R03), PA-11-237, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Gene-Environment Interplay in Substance Use Disorders (R01), PA-11-235, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism

Personalized Genomics for Symptom Management: Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R01), RFA-NR-11-003, National Institutes of Health; National Institute of Nursing Research

Personalized Genomics for Symptom Management: Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R21), RFA-NR-11-004, National Institutes of Health; National Institute of Nursing Research

The Electronic Medical Records and Genomics (eMERGE) Network, Phase II Coordinating Center (U01), RFA-HG-10-010, National Institutes of Health; National Human Genome Research Institute; The Electronic Medical Records and Genomics

Pharmacogenomics Research Network (U01/U19), RFA-GM-10-001, National Institutes of Health; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institute on Drug Abuse; National Institute on Mental Health; National Institute of Child Health

Genome-wide Association Studies of Treatment Response in Randomized Clinical Trials-Study Investigators (U01), RFA-HG-08-004, National Institutes of Health; National Human Genome Research Institute

Genome-wide Association Studies of Treatment Response in Randomized Clinical Trials - Coordinating Center (U01), RFA-HG-08-005, National Institutes of Health; National Human Genome Research Institute